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1 Abbreviations 
 
AP-1  Activating protein-1 
APP   Acute-phase proteins 
APR   Acute-phase response 
BCA   Bicinchoninic acid  
Bp  Base pair 
cDNA   Complementary deoxyribonucleic acid 
Ci  Curie 
Ct.  Threshold cycle 
dd H2O  Double distilled water 
DEPC   Diethylpyrocarbonate 
dNTP  Deoxyribonucleoside triphosphate 
DTT   Dithiothreitol 
EDTA   Ethylendiaminetetraacetic acid 
EGTA  Ethylene glycol tetraacetic acid 
ELISA   Enzyme-linked immunosorbent assay 
FCS   Fetal calf serum 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
HO-1   Heme oxygenase-1 
i.p  Intraperitoneal 
IFN-γ   Interferon gamma 
IL-1ß   Interleukin 1 beta 
IL-6   Interleukin 6 
Kb   Kilobase 
kDa   Kilodalton 
KO   Knockout 
LB-medium  Luria Bertani medium 
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LPS   Lipopolysaccharide 
Ltf   Lactoferrin 
MAPK   Mitogen Activated Protein Kinase 
MOPS  3-(N-morpholino) propanesulfonic acid 
mRNA   Messenger deoxyribonucleic acid 
NFκB  nuclear factor kappa-light-chain-enhancer of activated B cells 
OD  Optical density 
P/S   Penicillin / streptomycin 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PMSF  Phenylmethyl sulfonylfluoride 
RNase   Ribonuclease 
ROS  Reactive Oxygen Species 
rpm   Revolutions per minute 
RT   Room temperature 
RT-PCR  Reverse transcriptase-PCR 
SAA   Serum amyloid A 
SEM   Standard error of the mean 
STAT-3 Signal transducer and activator of transcription 3 
TAE   Tris acetate EDTA buffer 
TBS-T   Tris-buffered saline containing tween 20 
Tf   Transferrin 
TNF-α   Tumor necrosis factor alpha 
TO   Turpentine oil 
Tris   Tris-(hydroxymethyl)-aminomethane 
UV   Ultraviolet 
WT   Wild type 
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2 Introduction 
 
The immune system is an association of cells and molecules with specialized roles to defend the 
organism against infections and traumas. Fundamentally, the immune system responds in two ways: 
1. Innate (natural) responses are the instant outcome of any infection or injury and occur to the same 
extent however many times the infectious agent is encountered. The molecular components of innate 
responses include complement, acute phase proteins and cytokines such as IL-6, IL-1ß, TNF- and the 
interferons. The interferons are released by phagocytic cells (natural killer cells, neutrophils, monocytes 
and macrophages). 
2. Acquired (adaptive) responses follow the innate immune response and improve on repeated 
exposure to a given infection. Acquired responses involve the proliferation of antigen-specific B and T 
cells.  
Innate and acquired responses usually work together to eliminate pathogens (Delves and Roitt, 2000). 
 
2.1 Acute phase reaction (APR) 
 
The acute phase reaction (APR) is an innate immune response and is a physiological reaction of 
the body to injury, trauma or infection. It has been defined as ‘the entire array of metabolic and 
physiologic changes which occur in response to tissue injury or infection (Bayne and Gerwick, 
2001;Fulop, 2007). Its pattern varies depending on the type and intensity of the causative inflammatory 
agents (Siewert et al., 2004). From a clinical perspective, endotoxic shock and tissue trauma represent two 
severe homeostasis disturbances, leading towards the development of an acute phase response(Klein et al., 
2003). The inflammatory process resulting from infection or tissue injury is required for innate immune 
surveillance, optimal tissue recovery and subsequent restoration of normal physiological homeostasis 
(Vodovotz et al., 2006). This process is responsible for the general symptoms of acute phase reaction such 
as fever, somnolence, anorexia, muscular and joint pain, and adinamia (Ramadori and Christ, 1999).  
 
The usual outcome of the acute phase reaction is to successfully resolve the inflammatory process 
along with repair of damaged tissue, rather than persistence of inflammation which can lead to scarring 
and loss of organ function (Serhan and Savill, 2005;Sheikh et al., 2007). It is an important 
pathophysiologic phenomenon that replaces the normal homeostatic mechanisms with new set points that 
contribute to defensive or adaptive capabilities of the immune system. The functions of these changes are 
highly variable and diverse: some participate in initiating or sustaining the inflammatory process, others 
modulate it and still others have adaptive roles (Gabay and Kushner, 1999). 
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2.2 Metabolic changes during acute phase reaction 
 
The acute phase response results in a large number of changes, distant from the site or sites of 
inflammation and involving many organ systems. It mainly focuses on the orchestrated accelerated hepatic 
production of specific acute phase proteins (Moshage, 1997;Gabay and Kushner, 1999). Other responses 
include increased gluconeogenesis and mobilization of amino acids to the liver. Hypoferremia and 
hypozincemia are also among features of the APR (Liuzzi et al., 2005). Extensive metabolic changes also 
include suppression of pathways for cholesterol, fatty acid and phospholipid synthesis (Yoo and 
Desiderio, 2003).  
 
2.3 Acute phase proteins (APP) 
 
APR encompasses intertwined effects of inflammation and global tissue damage. It involves a 
complex interplay of interacting physiological and inflammatory elements working at multiple levels, 
resulting in the positive or negative regulation of various acute phase proteins (Lagoa et al., 2006). An 
acute phase protein (APP) has been defined as one whose plasma concentration increases (positive acute 
phase proteins) or decreases (negative acute phase proteins) by at least 25 percent during inflammation 
(Morley and Kushner, 1982). APPs are synthesized almost exclusively in the liver and are mostly 
glycosylated. They serve important functions in restoring homeostasis after infection or inflammation. 
These include homeostatic functions, microbial and phagocytic functions, antithrombotic properties and 
antiproteolytic actions which are important to contain protease activity at sites of inflammation only 
(Ramadori et al., 2009). 
Acute phase proteins can be divided into two groups:  
1. Type I acute phase proteins include SAA (serum amyloid A), CRP (C-reactive protein; human), 
complement C3, haptoglobin (rat), and α1-acid glycoprotein. They are induced by interleukin-6 
(IL-6), interleukin-1 (IL-1)-like cytokines which comprise IL-1, IL-1ß, tumour necrosis factor 
(TNF)-α and TNF- ß.  
2. Type II acute phase proteins are induced by IL-6-like cytokines which include IL-6 and its family 
members LIF (leukaemia inhibitory factor), IL-11, OSM (oncostatin M), CNTF (ciliary 
neurotrophic factor) and CT-1 (cardiotrophin-1). Type II proteins include fibrinogen, haptoglobin 
(human), α1-antichymotrypsin, α1-antitrypsin, and α2-macroglobulin (rat). 
 
In general, IL-6-like cytokines synergize with IL-1-like cytokines in the induction of type I acute 
phase proteins, whereas IL-1-like cytokines have no effect on or even inhibit the induction of type II acute 
phase proteins (Moshage, 1997). 
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2.4 Cytokines are the core mediators of acute phase reaction 
 
Cytokines are the imperative mediators of acute phase reaction. They are intercellular signalling 
molecules produced by activated immune cells (phagocytes). Most cytokines have multiple sources, 
multiple targets, and multiple functions. They operate both as initiators of linear signal cascades and as a 
part of complex interacting networks in regulating the production of acute phase proteins (Siewert et al., 
2004). They can function either locally in a paracrine or autocrine manner or at sites distant from their 
sites of production in a manner comparable to the endocrine hormones (Frost et al., 2002). The major 
cytokines involved in starting and developing the APR are IL1-β, TNF-α, IL-6 and IFN-γ (Barany, 2001). 
These cytokines promote cellular immunity. Transcription factor NF-κB is regarded as the principal 
mediator of the inflammatory response and is responsible for the transcription of more than 100 genes 
including IL1-β, TNF-α and IL-6 during inflammation (Elenkov et al., 2005). 
 
2.5 Iron participates in the conduction of acute phase response 
 
Iron is an essential element to almost all cell types due to its participation in numerous vital 
biological processes. It is an important factor required for growth and survival of various cell types 
(Sheikh et al., 2006) and plays a crucial role in oxidative stress as a major catalyst for hydroxyl radical 
formation via the fenton reaction (Tsukamoto et al., 1999). Under physiological conditions the free form 
of iron is practically insoluble and potentially toxic. Thus, iron is always found bound to specific ligands 
to render it both soluble and non-toxic. The toxicity of iron stems from its ability of redox cycling. The 
release of an electron from ferrous iron, if uncontrolled, may result in the formation of reactive oxygen 
species (ROS) capable of oxidizing lipids, proteins and DNA (Papanikolaou and Pantopoulos, 2005). 
However, many catalytic and other biological processes rely on the redox properties of iron; hence, iron 
must be available in a form which allows it to donate and accept electrons without causing non-specific 
damage (Graham et al., 2007).  
 
Acute phase reaction interacts with iron metabolism at several levels. Serum iron concentration 
decreases whereas the liver iron storage pool increases during inflammation, particularly due to increased 
sequestration of iron by macrophages. This sequestration is in part mediated by initiation of inflammatory 
cytokine-cascades (Barany, 2001;Oates and Ahmed, 2007). Iron stimulates ROS production in hepatic 
macrophages and in turn these ROS activate NF-kappa B, a stereotypical inflammatory transcription 
factor. Conversely, stimulation of hepatic macrophages with an agonist such as LPS induces ROS 
generation and ROS may initiate intracellular signalling that is dependent on a chelatable pool of iron.  
Thus, iron acts as a pro-inflammatory effector molecule via selective induction of the intracellular 
signalling for NF-kappa B activation (Xiong et al., 2004). A critical balance in iron levels is therefore 
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essential to sustain optimum shield by immune cells during infections to protect against free radical 
induced cellular damage and promotion of microbial growth, while at the same time providing adequate 
iron for essential metabolic functions in the body. Iron deficiency reduces the efficiency of immune cells 
whereas iron overload undermines immune protection and promotes free radical tissue damage (Ward and 
Conneely, 2004;Cronje et al., 2005). 
 
Studies have shown a correlation between iron concentration and immune cell functions. Cellular 
iron availability alters the proliferation and activation of lymphocytes and natural killer (NK) cells, 
modulates proliferation and differentiation of T cells, monocytes and macrophages, interacts with cell-
mediated immune effector pathways and modulates cytokine activities (Markel et al., 2007).Neutrophil 
and macrophage dysfunction has also been noted with low iron levels, as evidenced by deficient nitroblue 
terazoleum reduction and hydrogen peroxide formation in the respective cell lines of neutrophils and 
macrophages. In addition, certain DNA machinery components, such as ribonucleotide reductase, are iron-
dependent. Iron levels have also been shown to alter the proliferation of TH1 and TH2 cell-subsets, likely 
related to the difference in dependence of these cells on transferrin-related iron uptake (Markel et al., 
2007). TH2 clones possess larger pools of iron susceptible to chelation as compared with TH1 cells, making 
TH1 immune pathways more susceptible to changes in ambient iron concentrations (Marx, 2002).  
 
Changes in iron homeostasis accompany infectious or pro-inflammatory insults(Lagan et al., 
2008). Mammalian iron homeostasis is maintained through the concerted action of sensory and regulatory 
networks that modulate the expression of proteins of iron metabolism at the transcriptional and/or post-
transcriptional level. The liver expresses a complex range of molecules which regulate iron homeostasis 
(Crichton et al., 2002). The key modulators of iron homeostasis include hepcidin, haptoglobin, 
hemopexin, lactoferrin, and ferritin, which promote iron sequestration during inflammatory 
conditions(Nemeth et al., 2003;Sheikh et al., 2007). On the contrary, proteins that endorse iron 
accumulation, like transferrin and ferroportin, are suppressed during inflammation. The changes in the 
expression pattern of these iron regulatory proteins promote a hypoferremic state during acute phase 
reaction (Ballantyne, 1984). Thus, during the APR the increase in iron-binding plasma proteins represents 
an active mechanism for the sequestration of excess iron rather than a purely passive defence against the 
invading pathogens. 
2.6 Cytokines regulate the production of acute phase proteins including iron 
regulating proteins 
 
The cytokines produced during the inflammatory processes are the chief stimulators of acute phase 
protein production. The patterns of cytokine production and of the APR differ in different inflammatory 
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conditions. Acute phase changes reflect the presence and intensity of inflammation, and they have long 
been used as a clinical guide for diagnosis and treatment (Moriconi et al., 2009). 
 
During an acute inflammatory response serum iron has been shown to decrease (Sheikh et al., 
2007). Inflammatory hypoferremia is mediated in part by initiation of the inflammatory cytokine cascades. 
This has also been supported in murine studies, demonstrating that TNF- injections resulted in 
significantly lower serum iron levels and higher levels of circulating ferritin (Laftah et al., 2006). In 
addition, elevated IL-6 has been shown to result in hypoferremia, likely as a mechanism to limit bacterial 
iron availability. Decreased release of iron from ferritin stores and decreased absorption of iron from the 
intestine are part of this process (Hoppe et al., 2009). The final hypoferremic response, viewed clinically 
as the anemia of inflammation or chronic disease, is a result of elevated inflammatory cytokines and 
decreased anti-inflammatory cytokines (Ganz and Nemeth, 2009). Hypoferremia is a defining component 
of the anemia of inflammation. Specifically, IL-6, the proinflammatory cytokine responsible for inducing 
the majority of the acute phase genes, has been shown to induce hepatic production of hepcidin, the major 
iron regulatory hormone in response to inflammation (Malyszko et al., 2009). Hepcidin then inhibits both 
iron release by macrophages and absorption of dietary iron from the intestine and thereby produces 
hypoferremia (Munoz et al., 2009).  
 
2.7 Role of liver in acute phase response and regulation of iron homeostasis  
 
Liver is the main organ of the reticuloendothelial system (Tacke et al., 2009) and performs 
exceptional metabolic, synthetic and detoxifying functions. The central function of the liver for 
homeostasis and inflammatory responses is also underscored by its sole anatomical location, allowing 
continuous blood supply not only from the arterial system (hepatic arteries) but also from the 
gastrointestinal tract via the portal vein. Circulating blood cells, e.g. from the innate or adaptive immune 
system are pressed through a network of sinusoids allowing contact to a variety of intrahepatic cell 
populations, such as parenchymal liver cells (hepatocytes), endothelial cells, liver-resident macrophage 
(Kupffer cell) or lymphocyte populations, hepatic stellate cells and others (Fig. 1). Communication 
between these cell types and the regulation of hepatic functions are primarily achieved by cytokines ( 
Racanelli and Rehermann, 2006;Tacke et al., 2009).   
 
An important feature of the APR is the drastically altered protein biosynthetic profile in the liver. 
The liver is the central organ of the cytokine activity due to the fact that it hosts hepatocytes, which are 
highly susceptible to the activity of cytokines in a variety of physiological and pathophysiological 
processes. Moreover, the non-parenchymal cells of the liver, in particular Kupffer cells (KCs), the main 
population of tissue macrophages, are able to synthesize a variety of cytokines that may act systemically 
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on other body organs or in a paracrine manner on hepatocytes and other non-parenchymal liver cells and 
are responsible for the induction of acute phase proteins (APPs).  
 
 
 
 
Fig. 1: Cell populations in liver. The healthy liver consists of 60–80% hepatocytes; the other cell populations include 
biliary cells, liver sinusoidal endothelial cells (LSECs) lining the liver sinusoids, Kupffer cells (KC), and hepatic 
stellate cells (HSC) in the Dissé space between hepatocytes and LSECs. Besides, many immune cells entering from 
the circulation via hepatic arteries and portal vein branches, including neutrophils (PMN), monocytes (monos), 
dendritic cells (DCs), and lymphocytes (T, B, NK, and NKT cells) are found in liver (Tacke et al., 2009). 
 
Under normal circumstances the liver synthesizes a characteristic range of plasma proteins at 
steady concentrations. Most of the APPs are synthesized by hepatocytes which have important functions 
to perform. Higher plasma levels of APPs are required during the APR following an inflammatory 
stimulus. Synthesis of the major APPs can increase up to 1000-fold over normal levels. This group of 
proteins includes serum amyloid A (SAA) and either C-reactive protein (CRP) in humans or its 
homologue in mice serum amyloid P component (SAP). The concentration of negative APPs (e.g. 
albumin, transferrin, α-1 lipoprotein ) decreases in plasma during APR to allow an increase in the capacity 
of the liver to synthesize the positive APPs (Ramadori et al., 1985;Ramadori and Christ, 1999).  
 
Liver also performs a central role in iron metabolism and is the major site for iron storage in the 
body. It expresses a wide range of molecules involved in iron homeostasis (Graham et al., 2007). During 
APR liver enhances the production of all the major iron regulatory proteins for an effective removal of 
iron from the serum. Hepatocytes and liver resident macrophages, i.e. Kupffer cells, play an interactive 
role in this regard (Graham et al., 2007).  
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2.8 Role of skeletal muscle in the development of acute phase reaction 
 
Liver is the major site of synthesis of serologic and cytoplasmic acute phase proteins. On the other 
hand, skeletal muscle itself possesses both afferent and efferent arms of the innate immune system and 
contributes significantly to the development of APR (Frost et al., 2004). The metabolic response to tissue 
trauma and sepsis results in an accelerated muscle protein catabolism (Hasselgren et al., 1988) and these 
broken down proteins from the skeletal muscle tissue are converted into amino acids, taken up by the liver 
and used for augmented acute phase protein synthesis (Sayeed, 2000). Moreover, skeletal muscle is one of 
the largest organ in the body and acts as an endocrine organ by producing and releasing cytokines 
(Pedersen and Febbraio, 2008). Muscle derived cytokines not only contribute to the development of 
systemic acute phase response, but are also able to signal local inflammatory cells invasion into the 
muscle tissue (Tidball, 2005).  
 
2.9 Heme oxygenase-1 (HO-1) 
 
Heme oxygenase-1, also known as heat shock protein-32, is a non-secretory cytoprotective protein 
and is involved in the maintenance of normal physiology and repair of pathology (Immenschuh and 
Ramadori, 2000). Among the positive APPs, crucial role of intracellular HO-1 in maintaining normal body 
homeostasis during APR has been advocated using HO-1 knockout mice (Poss and Tonegawa, 1997). HO-
1 is induced by various stress stimuli to confer cytoprotection against oxidative stress (Poss and 
Tonegawa, 1997;Pae et al., 2008).  It catalyzes heme degradation to produce carbon monoxide, ferrous 
iron and biliverdin (Willis et al., 1996b). These end products are responsible for most of the biologic 
activity of HO-1, including anti-inflammatory, anti-apoptotic, anti-oxidative and anti-proliferative effects  
(Fig. 2) (Tron et al., 2005;Kinderlerer et al., 2009).  
 
Large amounts of free hemeproteins are released during hemolysis or rhabdomyolysis under 
various pathologic conditions, such as hemorrhage, hematoma, hemoglobinopathies, excessive blood 
transfusion and muscle injury (Wagener et al., 2001). Excess of free heme released from these 
hemeproteins under oxidative stress can be a major threat because it can catalyze the formation of reactive 
oxygen species (ROS) (Takahashi et al., 2004). Heme may also be released from mitochondrial P450 
cytochromes and contribute to inflammatory changes and cellular injury associated with oxidative stress 
(Beri and Chandra, 1993). The importance of heme in inflammatory processes in vivo is further 
emphasized by the rapid increased expression of hemoglobin and heme scavengers, haptoglobin and 
hemopexin, respectively, in response to inflammation. HO-1 induction during this process may act as a 
feedback mechanism (Wagener et al., 2001). The overexpression of HO-1 is known to be associated with 
an early resolution of inflammation (Willis et al., 1996) and protection against heme- and hemoglobin-
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mediated toxicity (Wagener et al., 2001). However, the induction of HO-1 is not only limited to 
catabolism of cellular heme, it is also strongly induced by non-heme stimuli as well during APR (Sheftel 
et al., 2007). 
 
  
Fig. 2: HO-1 pathway and biologic activities of HO-1 products (Kinderlerer et al., 2009).  
CO (carbon monoxide), GTP (Guanosine-5'-triphosphate), cGMP (Cyclic guanosine monophosphate). 
 
HO-1 expression is principally regulated at transcriptional level (Naidu et al., 2008) and 
transcriptional activation of HO-1 gene is an integral part of the cellular response to oxidative stress 
(Bauer and Bauer, 2002). Activator protein (AP)-1 is a major transcription factor that can transactivate 
HO-1 (Karin et al., 1997). The results of several studies have supported that the induction of HO-1 by 
oxidative stimuli, such as heme (Shan et al., 2004), sodium arsenite, cobalt chloride (Lu et al., 2000) and 
cobalt protoporphyrin (Shan et al., 2004) is mediated via AP-1 activation. Nuclear factor-κB (NF-κB) has 
also been implicated in the induction of HO-1 expression in response to different stimuli, such as hemin, 
cadmium (Chen et al., 2004), and LPS (Wijayanti et al., 2004). 
2.10 Lactoferrin (Ltf) 
 
Lactoferrin is an 80 kDa pleiotropic cationic monomeric glycoprotein, belongs to transferrin protein 
family (Montreuil et al., 1960) and is widely distributed all over the body. It is a key element in host 
immune system and is involved in the protection against a multitude of activities, including antibacterial, 
antiviral, antifungal and anti-tumor activities (Actor et al., 2009). Furthermore, lactoferrin sequence 
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includes a defensin-like peptide, lactoferricin, which shows antimicrobial properties that include iron 
sequestration, direct lytic activities and impaired binding of microbes to host cells (Markel et al., 2007). 
The lactoferricin domain of lactoferrin binds with high affinity to the lipid A of bacterial 
lipopolysaccharide (LPS) and hence defuses its effects (Legrand et al., 2004). Lactoferrin is a major 
constituent of milk, but it has also been measured in other body fluid including serum (Hallgren et al., 
1982). 
 
In the circulation and on mucosal surfaces, lactoferrin is incompletely saturated with iron and 
therefore can clear iron from the tissues (Griffiths et al., 2004). Reactive oxygen intermediates and other 
free radicals appear during acute inflammation (Koj, 1998). Lactoferrin can sequester iron at the site of 
inflammation and therefore prevent free iron from being available to catalyze harmful free radical 
reactions (Guillen et al., 2002). One unique property of lactoferrin that differentiates it from a closely 
related protein transferrin is that lactoferrin shows greater affinity for iron at pH values below 4.0 
(Vansnick et al., 1974). 
  
Lactoferrin is an important regulator of inflammation and immunity. It can inhibit granulopoiesis, 
suppress antibody production and regulate natural killer cell activity (Crouch et al., 1992). It can also act 
as an anti-inflammatory factor by regulating the production of inflammatory cytokines in a similar manner 
as that of anti-inflammatory cytokines(Yamaguchi et al., 2001).  Its receptors have been found on 
monocytes, macrophages and lymphocytes (Haversen et al., 2002). Mounting evidence implies that 
lactoferrin binding to target cells impinges on cellular signalling pathways, including mitogen-activated 
protein kinase (MAPK) and the nuclear factor κB (NFκB). Some reports also mention that lactoferrin 
enters the nucleus and directly activates target genes (Ward et al., 2005). Lactoferrin released from 
neutrophils at the site of inflammation interacts with mononuclear cells and suppresses the production of 
TNF-α and IL-1, the two major pro-inflammatory cytokines (Yamaguchi et al., 2001). However, 
lactoferrin can also favour the activation, differentiation and proliferation of immune cells, and this 
promoting activity has been related to a direct effect of lactoferrin on immune cells (Puddu et al., 1998). 
The site of synthesis of serum lactoferrin is still unknown. 
 
2.11 Exaggerated inflammatory response and IL-6 
 
In cases of prolonged systemic inflammation, APR remains persistently activated and if this 
inflammatory response is too exaggerated, it will start compromising the healthy tissue, therefore leading 
towards detrimental consequences (Vodovotz et al., 2006). Nevertheless, if the immune response is 
suppressed or not sufficient to eliminate the injuring agent, the inflammatory process will progress, 
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ultimately resulting in death (Chung et al., 2009). Therefore a critical balance between pro- and anti-
inflammatory mediators is vital.  
 
In order to avoid the spreading of inflammation, modulation of cytokine release is considered as 
an appealing strategy (Kobbe et al., 2008), but sharp differences in cytokine release patterns exist in APR 
resulting from different kinds of injuries (Ayala et al., 1991;Klein et al., 2003). Moreover, due to the 
inherent nonlinearity of APR, analyzing individual components in isolation may not elucidate how the 
entire system will behave to the presence or absence of a specific component (Day et al., 2006). However, 
in vivo studies using animal models attempt to reproduce features of human septic and traumatic shock 
conditions. The most important acute phase cytokines are interleukin-6, interleukin-1ß, TNF- and 
interferon-γ. They are mainly released by activated macrophages, but other cells are also able to produce 
them. 
 
Interleukin (IL)-6 is a pleiotropic cytokine that has important roles in the regulation of the 
immune response, inflammation and hematopoiesis. It is also known to regulate iron metabolism at a basic 
level and is the major regulator of hepatic acute phase protein synthesis in response to experimental 
inflammation by turpentine oil (TO) and LPS(Siewert et al., 2000; Siewert et al., 2004;Sheikh et al., 
2007). Progress in the study of IL-6 has increased our understanding of the pathological roles of this 
cytokine in different diseases and provided key evidence that antagonizing its activities can be used as a 
therapeutic strategy. Blocking IL-6 actions by use of a humanized antibody, tocilizumab, which targets the 
IL-6 receptor, has been proven to be therapeutically effective for a number of diseases (Nishimoto, 2006). 
However, the cost-benefit ratio of the negative to positive effects of blocking an inflammatory mediator 
varies with the situation (Klein et al., 2003). The role of IL-6 blockade on lactoferrin and HO-1 that 
constitute the positive healing mechanism during inflammation was the center of current study. 
2.12 Aims of the study 
2.12.1 Comparison of Ltf and HO-1 gene expression regulation in two acute phase reaction models 
in mice 
 
Acute phase reaction is a defense response that varies from individual to individual. During 
different acute inflammatory conditions, the pattern of induction of different acute phase proteins may be 
different in time and quantity. In order to diagnose and treat a pathological condition, it is very important 
to understand the regulation of different acute phase proteins and their mediators under different 
inflammatory conditions. In the current work, we aimed to investigate the regulation of hepatic HO-1 and 
lactoferrin gene expression regulation in two mouse models of acute phase inflammation. 
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Sepsis and tissue trauma by turpentine oil injection lead to different activation of intracellular and 
extracellular mediators in terms of expression pattern and concentration (Klein et al., 2003). Former is a 
representative animal model for gram negative bacterial infections resulting in activation of liver 
macrophages whereas the latter, a local sterile tissue necrosis, like in burns or surgical traumas, and liver 
becomes the target of locally released acute phase cytokines (Yang et al., 2005) While tissue injury elicits 
a distinct pattern of cytokine release into the blood by the inflammatory cells at the site of injury, 
endotoxins induce cytokine production by stimulated tissue macrophages at different organ sites, but 
mainly in the liver itself (Klein et al., 2003;Kobbe et al., 2008). To study lactoferrin and HO-1gene 
expression changes, we planned to use these two animal models. 
 
2.12.2 Role of IL-6 in the in vivo and in vitro gene expression regulation of Ltf and HO-1 during 
acute phase reaction in mice 
 
Regulation of HO-1 gene expression by interleukin-6 via STAT3 under acute phase conditions has 
been demonstrated (Tron et al., 2006). Accordingly, Yamaji et al. (2008) have described a significant 
reduction of HO-1 mRNA and protein expression in animals receiving CCl4 intraperitoneal injection after 
a pre-treatment with anti IL-6 antibodies. Recently, it has also been shown that interleukin-6 may be the 
major regulatory cytokine of HO-1 in a rat model of acute phase reaction, induced by intramuscular TO-
administration(Tron et al., 2005). Similarly, LPS is the key initiating factor in the pathogenesis of septic 
shock and is a potent inducer of HO-1 (Song et al., 2003). However, because of the complex signalling 
associations, it is still not clear, to which extent IL-6 is contributing to the regulation of HO-1 gene 
expression under different inflammatory conditions in vivo. 
 
Considering the central role of IL-6 in iron metabolism, we aimed to investigate the role of IL-6 to 
regulate hepatic HO-1 and Ltf gene expression in IL-6 treated mice. However, the diversity of pro- and 
anti-inflammatory effects of IL-6 indicate that IL-6 blockade may be useful in one inflammatory setting 
but harmful or non-beneficial in another setting (Riedemann et al., 2003). Therefore, in order to determine 
the specific role of IL-6 to regulate hepatic HO-1 and lactoferrin gene expression during APR we aimed to 
analyze the gene expression regulation of these two iron regulatory genes in IL-6 knockout mice during 
APR. 
 
2.12.3 Role of other acute phase cytokines to regulate hepatic HO-1 and Ltf expression in vivo and 
in vitro 
 
Although IL-6 is a principle mediator of APR, it is not the only cytokine regulating APR and iron 
metabolism. Therefore, in order to determine the particular role played by other acute phase cytokines to 
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regulate hepatic HO-1 and Ltf gene expression, we aimed to study the gene regulation of Ltf and HO-1 in 
liver after intraperitoneal injections of different pro-inflammatory cytokines. These cytokines included 
TNF-, IL-1ß and IFN-γ. 
 
2.12.4 Role of cytokines in the development of acute phase response 
 
Dysregulated cytokine actions after liver injury can result in excessive apoptosis, leading towards 
detrimental consequences. In order to determine the role of different cytokines to induce APR-related 
inflammation, and in particular to analyze the impact of IL-6 absence on the development of acute phase 
reaction, we aimed to determine gene expression regulation of serum amyloid A-1, which is a classical 
marker of acute inflammation, in the liver of mice after different treatments. 
 
2.12.5 Evaluation of Ltf and HO-1 gene expression in skeletal muscle of TO- and LPS-treated wild 
type and IL-6 knockout mice 
 
Muscle wasting is a common feature of systemic inflammation and malignant diseases. The 
primary cause is increased proteolysis (Lecker et al., 1999). Skeletal muscle wasting has been associated 
with elevations in circulating inflammatory cytokines (Petersen et al., 2009).  IL-6 is an important 
messenger in systemic and skeletal muscle metabolism and profoundly alters the amino acid turn over 
during inflammatory conditions (van Hall et al., 2008). HO-1 and Lactoferrin have protective roles during 
acute inflammation and might represent the mechanisms for protecting skeletal muscle from excessive 
catabolism during inflammation. In order to look into their specific roles in controlling skeletal muscle 
loss during inflammation we aimed to study the pattern of regulation of these two genes in the injured and 
non-injured muscle of TO- and LPS-treated wild type and IL-6 knockout mice. 
2.12.6 In vitro studies 
 
In order to support our in vivo studies to examine the role of different cytokines, we planed to 
determine the regulation of HO-1 and lactoferrin expression by the in vitro stimulations of these acute 
phase cytokines to hepatocytes and hepa 1-6 cells. 
 
 
 
 
 
 
 
  
18
3 Materials and Methods 
 
3.1 Materials 
 
All the chemicals used were of analytical grade and were purchased from commercial sources. 
3.1.1 Animals 
 
Male IL-6 Knockout mice (B6.129S2-IL6tm1Kopf/J) were purchased from Jackson Laboratories 
USA, whereas wild type C57Bl6 mice were purchased from Harlan-Winkelmann, Germany. All the 
animals were of 6-8 weeks of age. Animals were fed standard laboratory chow, given free access to water, 
and maintained on a 12h: 12h light-dark cycle. Animals were used for the experiments not earlier than one 
week after arrival. All animals were handled in accordance with the institution’s guidelines, the German 
convention for the protection of animals and the National Institutes of Health guidelines. 
 
3.1.2 Bacterial strain 
 
NovaBlue Singles™ Competent Cells from Novagen (Germany) were used for bacterial 
transformations. 
 
3.1.3 Plasmid 
Human lactoferrin cDNA in pCMV6-XL5 vector was obtained from Origene (USA) for making 
lactoferrin Northern probe. 
3.2 Methods 
 
3.2.1 Animal treatments and generation of acute inflammatory response 
 
Mainly two types of animal models were used to study HO-1 and lactoferrin gene expression 
regulation during APR. In the first model, mice were injected with 10ml/kg turpentine oil i.e., 100µl in 
each of the hind limb muscle. This animal model of localised tissue injury was carried out in IL-6 
Knockout mice and their wild type C57Bl6 mice. In the second animal model, mice were intraperitoneally 
injected with 50µg of LPS from E.coli (Sigma Aldrich). This animal model of sepsis was also performed 
in IL-6 knockout mice and wild type C57Bl6 mice. Control animals received no treatment. Animals were 
sacrificed at different time points from 0h to 24h after treatment, using pentobarbital sodium anaesthesia 
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(Hallbergmoos, Germany). Livers and skeletal muscles were excised, rinsed shortly in physiological saline 
solution and snap frozen in liquid nitrogen and stored at -80 ºC.  
Animal Strain Treatment Treatment 
time points 
Total 
animals 
per Test 
series 
Control 
TO 20 Male wild type 
C57BL/6 J LPS 20 
4 
TO 20 Male IL-6 
Knockout mice 
(B6.129S2-
IL6tm1Kopf/J) 
 
LPS 
 
 
2h, 4h, 6h, 
12h, 24h 
20 
4 
 
In another series of experiments, wild type mice were injected intraperitoneally with 1000 units of 
murine IL-6 or 2µg of TNF-, or 2µg of mouse recombinant lL-1ß. Another group of mice was injected 
with recombinant murine IFN-γ. Control animals received no treatment. The livers of the cytokine-treated 
animals were excised at different time points till 48 hours, snap frozen in liquid nitrogen and stored at -80 
ºC.  
Animal Strain Treatment Treatment time 
points 
Total 
animals 
per Test 
series 
Control 
Interleukin-6 2h, 6h, 12h, 24h 12 
TNF- 1h, 3h, 6h, 12h, 
24h, 36h, 48h 
21 
IL-1ß 1h, 3h, 6h, 12h, 
24h, 36h 
12 
Male wild type 
C57BL/6 J  
IFN-γ 0.5h, 1h,2h, 4h, 6h, 
12h, 24h, 36h, 48h 
22 
8 
3.2.2 Blood samples 
 
Blood was collected from inferior vena cava in serum collecting tubes, allowed to clot overnight 
at 4ºC and centrifuged for 20 minutes at 4000xg. Serum was collected and stored at -20C. 
3.2.3 Stock solutions 
 
All solutions were prepared as described in ‘‘Basic methods in Molecular Biology’’ by Leonard 
G. Davis (1986). 
  
20
3.2.4 Methods of cell biology 
 
3.2.4.1 Isolation of mouse hepatocytes 
Hepatocytes were isolated from male C57BL/6J mice livers by circulating perfusion with 
collagenase essentially as described previously (Chua et al., 2004). The liver was perfused in non-
recirculative mode through the portal vein with 150-200ml CO2-enriched preperfusion medium at a flow 
rate of 10 ml/minute for 5 minutes so that the liver was free from blood. To break down components of 
extracellular matrix, the liver was then perfused in recirculative mode with 0.01% collagenase Type I for 5 
minutes at a rate of 12 ml/minute.  
 
After perfusion, the liver was excised and transferred into a sterile glass beaker filled with 
Dulbecco modified Eagle medium containing 10% fetal calf serum, 1% penicillin/streptomycin, 1% L-
glutamin, 10nM dexamethasone and 10nM insulin. Glisson’s capsule, i. e. collagen tissue around the liver, 
was carefully removed and discarded. To obtain a cell suspension, the tissue was disrupted mechanically 
using sterile forceps. Connective tissue and remainder of the liver capsule as well as big cell aggregates 
were removed by filtration of the primary cell suspension through a nylon mesh (pore size 79μm). Non-
parenchymal cells and cell debris were removed by centrifugation (200xg, 2minute, 4°C) in wash medium. 
After centrifugation, hepatocytes were suspended in Dulbecco modified Eagle medium with additives. 
3.2.4.2 Media and solutions for hepatocyte preparation and culture 
All media and solutions for cell culture were prepared in double distilled water, were further 
purified by sterile filtration and stored at 4°C. All solutions were prepared no more than one day before 
the cell isolation. 
Preperfusion medium 
 For 1 l Final concentration 
 
EGTA 
 
95.1 mg 
 
0.25 mM 
 
Krebs-Ringer stock solution 
 
to 1 l 
 
 
Collagenase perfusion medium 
 For 100 ml Final concentration 
 
HEPES 
 
360 mg 
 
15 mM 
 
CaCl2×2H2O 
 
58.8 mg 
 
4 mM 
 
Collagenase 
 
50 mg 
 
 
Krebs-Ringer stock solution 
 
to 100 ml 
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The medium was prepared directly prior to isolation, equilibrated with carbogen for 30 minutes and finally 
sterile filtered. 
Wash medium 
 For 1 l Final concentration 
 
HEPES/NaOH pH 7.4 
 
4.77 g 
 
20 mM 
 
NaCl 
 
7.00 g 
 
120 mM 
 
KCl 
 
0.36 g 
 
4.8 mM 
 
MgSO4×7H2O 
 
0.30 g 
 
1.2 mM 
 
KH2PO4 
 
0.16 g 
 
1.2 mM 
 
Bovine serum albumin 
 
4.00 g 
 
0.4% 
 
ddH2O 
 
to 1 l 
 
 
 
3.2.4.3 IL-6 treatment of primary culture of mouse hepatocytes 
 
Primary mouse hepatocytes were treated with various concentrations of murine IL-6 on the next 
day after plating. The medium was changed 6h prior to treatment; the stimuli were diluted to the required 
concentrations in the culture medium and added directly to the culture dishes by pipetting. The same 
amount of normal culture medium was pipetted to the dishes with cells which served later as experimental 
controls. To stop the culture, dishes with cells were taken from the incubator; the cells were washed with 
phosphate buffered saline, pH 7.4, and frozen at –80°C for subsequent RNA or protein isolation. 
Alternatively, cells were subjected to lysis immediately after washing. 
3.2.4.4 Culture and stimulation of murine Hepa 1-6 cells 
 
Murine hepatoma cells Hepa 1-6 were grown in DMEM medium containing L-Glu, P/S and FCS. 
Cells were plated in the Petri-dishes for 2-3 nights till 80-100% confluence, and were then treated with 
IFN-γ (murine), TNF- (murine), IL-1ß (murine) and IL-6 (murine) in a time dependent manner and were 
harvested after 3h, 6h, 12h and 24h of stimulation. Cytokines (100ng/ml) were mixed in the medium in 
15ml falcon tubes under the hood. Cells were gently washed twice with sterilised PBS. The medium in the 
plates was replaced with the cytokines containing medium. In control the medium was changed with a 
new normal medium. Medium was collected at the end of treatment time and the cells were snap-frozen in 
liquid nitrogen and stored in freezer. 
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3.2.5 Methods of molecular biology 
 
3.2.5.1 Transformation of E. coli 
The competent bacteria (100μl) were thawed on ice. Next, 100ng of plasmid DNA was added 
directly to the competent cells and the mixture was incubated on ice for 30 minutes. Cells were subjected 
to heat shock by incubating at 42°C for 30 seconds and were subsequently incubated on ice for 2 minutes. 
Afterwards, 300μl of SOC medium was added to the cells followed by 40 minutes incubation at 37°C 
under continuous shaking at 225 rpm. After chilling on ice, transformed cells (50μl) were spread over LB-
ampicillin agar dishes and incubated for 18 h at 37°C. 
 
3.2.5.1.1 Purification of plasmid DNA 
 
A single colony of transformed competent E. coli was picked from LB-ampicillin agar dish and 
was inoculated into 2 ml of ampicillin-containing LB medium, followed by incubation for 12 h at 37°C 
with vigorous shaking at 300 rpm. Afterwards, 850μl aliquot of bacterial suspension was mixed with 
150μl of sterile 87% glycerol and stored at – 80°C as a bacterial stock, other portion of this starter culture 
was diluted 1:1000 in LB medium, i.e. 100μl of bacterial suspension was inoculated into 100 ml of LB 
medium and bacteria were grown at 37°C for 12-16 h with vigorous shaking at 300 rpm to a density of 
approximately 3-4×109 cells per ml, which corresponds to OD600 of 1-1.5. The bacterial cells were 
harvested by centrifugation at 6,000 g for 15 minutes at 4°C. Purification of plasmid DNA from 
transformed bacteria was performed using ‘EndoFree™ Plasmid Maxi Kit’ (Qiagen). 
 
The DNA pellet obtained was dissolved in endotoxin-free TE buffer.The integrity and purity of 
the obtained plasmid DNA was controlled by agarose gel analysis. 
 
3.2.5.2 Real-time polymerase chain reaction 
3.2.5.2.1 Reverse transcription 
 
The cDNA was generated by reverse transcription of 1μg of total RNA with 100nM of dNTPs, 
50pM of primer oligo (dT)15, 200U of moloney-murineleukemia virus reverse transcriptase (M-MLV RT), 
16 U of protector RNase inhibitor, 1x RT buffer and 2.5μl of 0.1M DTT for 1h at 40°C.  Gene expression 
of murine lactoferrin, hemeoxygenase-1, IL-6, TNF-, IL-1ß, IFN-γ, SAA-1 and of house keeping genes 
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GAPDH and ß-actin was analyzed using Platinum SYBR® Green qPCR mix (Invitrogen). Primer 
sequences used are given in Table 1. 
3.2.5.2.2 Thermal cycler amplification program 
 
The amplification was performed at 50°C for 2 minutes, 95°C for 2 minutes, 95°C for 15 seconds 
to 60°C for 30 seconds for 45 cycles in an ABI prism 7000 sequence detection system. All samples were 
assayed in duplicate. The PCR amplification program was followed by dissociation curve protocol for 
controlling the specificity of the PCR products. Curves of amplification were analyzed to measure the Ct 
value in the linear range of the amplification. The results were normalized to the housekeeping gene and 
fold change expression was calculated using Ct values by Prism Graph Pad 4 software. 
 
3.2.5.3 Primers designing 
 
Primers for different genes were designed using the program “Primer3 Input (version 0.4.0)” and 
the gene bank data (http://www.ncbi.nlm.nih.gov). All the primer sets used for real-time PCR are listed in 
Table 1. 
 
Table 1: Primer sequences used for real-time PCR analysis. 
  Forward Primer Reverse Primer 
Mouse HO-1 TTACCTTCCCGAACATCGAC TCCTCTGTCAGCATCACCTG 
Mouse ß-actin ATTGTTACCAACTGGGACGACATG CGAAGTCTAGAGCAACATAGCACA 
Mouse TNF-  CAAACCACCAAGTGGAGGAG GTGGGTGAGGAGCACGTAGT 
Mouse IL-6 TTCCATCCAGTTGCCTTCTTGG TTCTCATTTCCACGATTTCCCAG 
Mouse IL-1ß TACAGGCTCCGAGATGAACA AGGCCACAGGTATTTTGTCG 
Mouse IFN-γ GCGTCATTGAATCACACCTG TGAGCTCATTGAATGCTTGG 
Mouse SAA-1 ATTTGTTCACGAGGCTTTCC TTTTCTCAGCAGCCCAGACT 
Mouse GAPDH AGAACATCATCCCTGCATCC CACATTGGGGGTAGGAACAC 
Mouse Lactoferrin CGAAGCACGAATGACAAAGA 
 
ACAAAGCCAATGGCAGACTC 
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3.2.5.4 Isolation of total RNA 
 
3.2.5.4.1 RNA isolation procedure using silica columns 
 
Isolation of total RNA from cultured murine hepatocytes and hepa 1-6 cells was performed using 
the NucleoSpin® RNAII kit (Macherey-Nagel) in accordance with the manufacturer’s protocol for 
cultured animal cells. The RNA obtained was eluted with 60μl of RNase free H
2
O.  
 
3.2.5.4.2 Isolation of RNA by density-gradient ultracentrifugation 
 
Total RNA from liver and the skeletal muscle was isolated by means of guanidine isothiocyanate 
extraction, cesium chloride density-gradient ultracentrifugation and ethanol precipitation according to 
method of Chirgwin et al. (1979). 
About 100mg of frozen tissue was homogenized with ultra-turrax TP 18/10 homogenizer 3 times 
for 10 seconds each in 3ml of ice-cold GITC buffer with freshly added antifoam A (Sigma). The 
homogenates were centrifuged for 10 minutes at 3,500xg in a Rotixa/RP centrifuge (Hettich) at 4°C to 
pellet connective tissue and large cell debris. 
 
To prepare the gradient, 2ml of CsCl buffer was poured into 5ml polyallomer ultracentrifuge tubes 
(6 per preparation). The cleared guanidine lysed samples were carefully layered on top of the CsCl buffer. 
The samples were centrifuged overnight (21h) at 35,000xg in a Kontron TST55 rotor at 20°C. The 
supernatants were carefully removed by aspiration and the transparent gelatin-like RNA pellets were 
gently washed (preserving undisturbed) with 200μl of 70% ethanol at room temperature. Each pellet was 
resuspended in 200μl of RNase-free water by pipetting and transferred into sterile 1.5ml Eppendorf tube. 
 
The RNA was precipitated with 450μl of 100% ethanol in the presence of sodium acetate, pH 5.4 
(20 μl of 2 M solution per pellet) overnight at –20°C. The RNA precipitates were centrifuged for 30 
minutes at 12,000xg in an Eppendorf bench-top centrifuge at 4°C to get RNA pellet. Supernatants were 
discarded and pellets were washed with 200μl of ice-cold 70% ethanol to remove all traces of sodium 
acetate. The RNA precipitates were centrifuged as described above, the supernatants were discarded and 
the pellets were dried for 30 minutes at room temperature. The RNA pellets were reconstituted in 100μl of 
RNase-free water. 
 
 
3.2.5.5 Northern blot analysis 
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3.2.5.5.1 Preparation of Northern probe by amplification of DNA with conventional PCR  
 
To prepare the Northern probe for GAPDH, SAA-1, HO-1 and transferrin, PCR amplification was 
performed using the Go Taq ® Green master mix (Promega, Mannheim, Germany), using specific 
primers, as mentioned in Table 1. The cDNA was denatured at high temperature (Stage 1: 2 minute 
incubation at 95°C to ensure complete denaturation of the target DNA). It was followed by repetitive 
cycles of denaturation, annealing and extension for 45 repeats (stage 2: denaturation for 30 seconds at 
95°C, annealing for 30 seconds at 60°C and extension for 1 minute at 72°C). Final extension of the DNA 
was performed in stage 3 at 72°C for 5 minutes. Finally, the PCR product was stored at 4°C for infinity. 
 
Go Taq ® Green master mix also contains blue and yellow dyes that allow monitoring the 
progress during electrophoresis. To verify the specificity and purity of the PCR product, the size of the 
product was determined by agarose gel electrophoresis. For this purpose, an aliquot of 10μl from the PCR 
reaction mix was loaded on 1% agarose gel made in 1x TAE and 5-8μl of ethidium bromide (10 mg/ml). 
 
3.2.5.5.2 RNA filter preparation and DNA probe labelling 
 
Total RNA (5-10µg per sample) was size fractionated in 1% agarose-formaldehyde gels by 
electrophoresis, transferred to nylon membranes (Amersham Pharmacia Biotech, Freiburg, Germany) by 
using the capillary transfer systems and cross-linked by using ultraviolet light. The DNA probe was 
labelled with 40–60mCi of (α-32P)-labelled deoxy-cytidine-triphosphate (3000Ci/mmol) by nick 
translation using a Nick Translation Kit (Invitrogen) or by random primed DNA labelling, using NE 
Blot® Kit (New England Biolabs). The probes were purified from non-incorporated radiolabeled 
nucleotides on NICK columns prepacked with Sephadexs G-50 (Amersham Pharmacia Biotech).  
 
3.2.5.5.3 Hybridization 
 
The RNA membrane was pre-hybridized for 2 h with 12ml of QuikHyb® hybridization solution at 
68°C to prevent unspecific binding. The labelled DNA and salmon sperm DNA were mixed and the 
mixture was denatured for 5 minutes at 95°C and chilled on ice for 3-5 minutes. The probe was 
centrifuged shortly and mixed with QuikHyb® solution in the hybridization tube. The hybridization was 
carried out for 2h at 68°C in a hybridization oven. The volume of the radiolabelled DNA used for an 
appropriate volume of QuickHyb (Stratagene, TX, USA) solution was calculated as follows: 
V [α-32P]DNA = (Vquick hyb × 1,000,000) / ß-radioactivity of cDNA in 1μl 
Vsalmon sperm DNA =2× V [α-32P] DNA 
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3.2.5.5.4 Washing 
 
After hybridization, the membrane was rinsed twice in the hybridization tube with 30ml of 
2×SSC/0.1% SDS. Then 2x SSC with 0.1% SDS was used for 10 minutes at room temperature and 0.1x 
SSC/0.1% SDS for two washings at 55°C in the hybridization oven. Afterwards, the membrane was 
transferred to a plastic tray and further washed in 2×SSC/0.1% SDS with shaking at room temperature. 
The radioactivity was controlled to 100cpm by the washing steps. The membrane was packed in a cling 
film, placed in an X-ray film cassette and exposed to X-ray film, which was developed afterwards. 
 
3.2.6 Biochemical methods 
 
3.2.6.1 Protein extraction from liver tissue and cultured hepatocytes 
 
3.2.6.1.1 Preparation of tissue homogenates 
 
All steps were performed at 4°C to prevent proteolytic degradation of the proteins. About 100mg 
of frozen tissue was homogenized with Ultra-Turrax TP 18/10 model homogenizer 3 times for 10 seconds 
each in 10 volumes of 50 mM Tris-HCl buffer, pH 7.4, containing 150mM NaCl, 1 mM EDTA, 1% Triton 
X-100, 1mM PMSF, 1mM benzamidine, 1μg/ml leupeptin, 10μM chymostatin, 1μg/ml antipain, 1μg/ml 
pepstatin A. Crude homogenates were passed 5 times through a 22G injection cannula connected to a 
syringe. To pellet the nuclei and other suspended material, crude homogenates were centrifuged for 5 
minutes at 10,000xg (4°C) and the protein concentration of supernatants was determined using the BCA 
protein assay reagent kit (Pierce, Bonn, Germany). Prepared homogenates were dispensed in aliquots and 
stored at −20°C until use. 
3.2.6.1.2 Preparation of cell lysates 
 
All steps of the procedure were performed at 4°C to prevent proteolytic degradation of the 
proteins. The cells frozen in the culture dishes were thawed on ice. 1x ice-cold lysis buffer, supplemented 
with protease inhibitors was added to the cells (360μl per 6 cm dish), followed by incubation on ice for 15 
minutes. Afterwards, the cells were scraped with a disposable scraper, transferred to new tubes and passed 
5 times through a 22G injection cannula connected to a syringe. The lysates were then centrifuged for 5 
minutes at 10,000xg (4°C) and the protein concentration of supernatants was determined by BCA method 
using the kit from Pierce. Prepared lysates were aliquoted and stored at −20°C until use. 
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3.2.6.2 Western blot analysis 
Protein samples were denatured in electrophoresis buffer (50 mM Tris-HCl, pH 6.8, 2% sodium 
dodecyl sulfate, 10% glycerol, 50 µg/ml bromphenol blue, 2% ß-mercaptoethanol) at 95°C for 10 minutes 
and 30-50μg of total protein was subjected to  gel electrophoresis using NuPAGE® Novex 4-12% Bis-Tris 
Gels (Invitrogen), using XCell SureLock® Mini-Cell (Invitrogen). The Rainbow™ coloured-protein-
markers (Amersham Pharmacia Biotech) were used as molecular weight standards. The proteins from gel 
were shifted to a nitrocellulose membrane using XCell II™ Blot (invitrogen). 
The membranes were blocked in Tris-buffered saline containing 0.1% Tween 20 (TBS-T) and 5% 
nonfat dry milk at 4°C overnight and processed for immunodetection using a rabbit polyclonal antiserum 
against HO-1 or Ltf (in TBS-T with 0.5% milk) for 2 h at room temperature. After a subsequent washing 
step, the membrane was incubated with a peroxidase-conjugated secondary antibody. Visualization of 
immunoreactive bands was performed using AmershamTM ECLTM Western blotting detection reagent and 
the signal was detected by short exposure to X-ray film (Fuji, Duesseldorf, Germany). To ensure equal 
loading of proteins, the blots were stripped and reprobed with anti-ß-actin antibody (1:5000 dilution in 
TBS-T with 0.5% milk; 1 h, room temperature). 
Primary antibodies were used in the following dilutions: 
Antibody Used dilution 
 
anti-HO-1 rabbit polyclonal antiserum 
 
1:1000 
 
anti-Ltf rabbit polyclonal antiserum 
 
1:5000 
 
anti-β-actin mouse monoclonal antibody 
 
1:3000 
 
Secondary HRP-conjugated antibodies were used in the following dilution: 
Antibody Used dilution 
 
Donkey anti-rabbit whole Ig 
 
1:5000 
 
Rabbit anti-mouse Ig 1:5000 
 
 
 
3.2.6.3 Nuclear protein isolation and gel mobility shift assay 
Nuclear proteins were isolated as described by Essani et al. (1996). Briefly, liver tissue (0.1-0,2g) 
was homogenized in 1ml of buffer A (10mM Hepes-KOH, pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM 
DTT, 0.4mM PMSF, 1mM NaVO3, 2μg/ml pepstatin and 2μg/ml apoprotinin) with a Potter homogenizer.  
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These homogenates were then centrifuged at 600xg for 10 minutes at 4ºC and the pellet was resuspended 
in 1ml of buffer B (Buffer A with 0,1% triton X-100). This mixture was incubated for 10 minutes on ice 
and then centrifuged at 850xg for 10 minutes at 4ºC.  The supernatant was discarded and the nuclear pellet 
was washed again with buffer A, as before, and then resuspended in buffer C (20mM Hepes-KOH, pH7.9, 
1.5mM MgCl2, 0.42mM NaCl, 0.2mM EDTA, 20% glycerol, 0.5mM DTT, 0.4mM PMSF, 1mM NaVO3, 
pepstatin and apoprotinin as above) and was incubated at 4 °C for 30-60 minutes with gentle agitation. 
Nuclear debris was pelleted by centrifugation at 12000xg for 15 minutes and supernatant-containing 
nuclear proteins were stored at −80 °C until use. DNA consensus sequence for AP-1 and NFκB and Gel 
shift core assay system from Promega were used according to manufacturers’ instruction to study DNA 
binding activity of these two transcription factors. 
3.2.6.4 Enzyme-linked immunosorbent assay (ELISA) 
 
For detection of cytokines in serum, Quantikine® IL-1ß and TNF- ELISA kits from R&D 
systems were used. For serum IL-6 a sandwitch ELISA kit from Pierce Biotechnology was used. To 
measure the changes of lactoferrin concentration in serum, a sandwich enzyme immunoassay (Uscn Life 
Science Inc. Wuhan) for murine lactoferrin was used. Samples were processed according to the 
manufacturer's instructions. Samples consisted of sera from TO- and LPS-treated wild type and IL-6 
knockout mice at different time points after the induction of acute phase reaction. 
 
3.2.6.5 Iron measurement 
 
3.2.6.5.1 Principle 
 
Iron bound to transferrin is released in an acidic medium as ferric iron and is then reduced to 
ferrous iron in the presence of ascorbic acid. Ferrous iron forms a blue complex with ferene. The 
absorbance at 595 nm is directly proportional to the iron concentration. 
 
Transferrin (Fe3+)2                     
Ascorbic acid, Buffer                 2 Fe2+ +transferrin 
Fe2+ + 3 Ferene                                                               Ferrous Ferene (blue complex) 
 
Reagents 
   Final 
concentration 
 
 
R1: Acetate buffer pH 4.5 800 mM/l 
 
 
 Thiourea  90 mM/l  
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R2: Ascorbic acid  45 mM/l 
 
 
 Ferene  0.6 mM/l 
 
 
 Thiourea  20mM/l 
 
 
Standard 
 (Should be protected from light) 
 
 100μg/dl (17.9 μM/l) 
 
3.2.6.5.2 Assay Procedure 
 
To determine the serum iron level, 100 μl of the serum sample along with 1000μl of the reagent 1 
was taken in the reaction tube. For blank 100μl of dd H2O was used. The sample and reagent 1 was mixed 
thoroughly, incubated for 5 minutes and read the absorbance (A1). After that 250μl of the reagent 2 was 
added, mixed thoroughly and the absorbance (A2) was read after 10 minutes of incubation. 
 
3.2.6.5.3 Calculations 
 
ΔA = [(A2- 0.82 A1) sample/Std.] – [(A2-0.82A1) blank] 
The factor 0.82 compensates the decrease of the absorbance by addition of reagent 2. The factor is 
calculated as follows: 
 
(Sample +R1)/Total volume. 
 
This compensation is necessary as a high sample volume is used. 
 
Iron [μg/dl] = ΔA Sample/ΔA Std/Cal × Conc. Std. /Cal [μg/dl] 
Conversion factor Iron [μg/dl] × 0.1791 [μM/l] 
 
3.2.6.5.4 Measuring range 
The test has been developed to determine iron concentrations within a measuring range from 5-
1000μg/dl (0.9-179μM/l). When values exceed this value samples should be diluted 1 + 2 with NaCl 
solution (9 g/l) and the results multiplied by 3. 
 
3.2.6.5.5 Specificity and sensitivity 
The test was specific and no interference was observed by conjugated and free bilirubin up to 60 
mg/dl, hemoglobin up to 100 mg/dl, lipemia up to 2000 mg/dl triglycerides, and copper up to 200μg/dl. 
The lower limit of detection for the test is 2μg/dl (0.4μM/l). 
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3.2.7 Safety measures 
All operations with genetically modified organisms and plasmid DNA were performed in accordance to 
the ‘‘Gentechnikgesetz’’ of 1990 and to the rules prescribed by the ‘‘Gentechnik-Sicherheitsverordnung’’ 
of 1990. Ethidium bromide, formaldehyde, DEPC and other chemicals deleterious for the environment 
when used in the course of the work were carefully managed and disposed properly in accordance with 
institutional guidelines. All the operations with radioactive chemicals were performed in a radioactivity 
class II laboratory and the radioactive waste was disposed off according to the institutional instructions. 
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4 Results 
 
4.1 Analysis of magnitude of induction of acute phase response 
 
In order to evaluate the magnitude of induction of APR in IL-6 knockout (KO) mice in 
comparison to their respective wild type counterparts, we used measurement of SAA-1 gene expression as 
a positive marker for generation of acute phase response. In TO-treated wild type mice (Fig. 3) significant 
augmentation of hepatic SAA-1 mRNA was seen at 4h (P<0.0001) and 12h (0.0005), whereas in case of 
TO-treated IL-6 knockout mice (Fig. 8) significant increase of SAA-1 mRNA was seen at 4h (18.65 ± 
4.17 fold change, P= 0.0241) and 24h (4.35 ± 0.97 fold change, P= 0.0409) after TO-Injection. However, 
the interesting difference between wild type and IL-6 knockout mice was, that in knockout mice at 4h was 
the peak augmentation of SAA-1 messenger RNA and then it started to decline, but in wild type mice 
although statistically non-significant, increased hepatic SAA-1 mRNA levels still could be seen even at 
24h (171.00 ± 56.36 fold change). In LPS treated wild type mice  (Fig. 4) statistically significant 
intensification of hepatic SAA-1 mRNA was observed at 4h (80.23 ± 23.49 fold change, P=0.0433), 12h 
(35.91 ± 4.03 fold change, P= 0.0032) and 24h (40.80 ± 4.36 fold change, P=0.0028), whereas in LPS-
treated IL-6 knockout mice  (Fig. 9) significant increase of SAA-1 gene expression was evident at 4h 
(265.71 ±  80.78 fold change, P= 0.0465) and 6h (137.63 ± 11.52 fold change, P= 0.0013). Considering 
the fold change and the pattern of decline of SAA-1 messenger in livers of LPS treated animals at different 
time points, it appeared that the absence of IL-6 resulted in a delayed resolution of inflammation in 
knockout mice (150.89 ± 59.78 fold change) as compared to their wild type equivalents( 40.80 ± 4.36 fold 
change). 
 
4.2 The pattern of changes in hepatic HO-1 gene expression during APR is 
dependent on the nature of insult 
 
RT-PCR analysis revealed a significant upregulation of hepatic HO-1 gene expression after TO (Fig. 3) or 
LPS (Fig. 4) induced acute phase reactions in wild type mice. However, the augmentation pattern of HO-1 
mRNA was different in both types of acute phase responses. LPS injection resulted in an immediate peak 
of HO-1 mRNA at 2h (30.65 ± 8.66 fold change, P= 0.0209), whereas TO-injection caused a significant 
augmentation of HO-1 mRNA at 2h (32.72 ± 0.99; P<0.0001), but the peak was seen at 4h (57.33 ± 3.8 
fold change, P<0.0001). 
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Figure 3: 
HO-1 and SAA-1 gene expression regulation in the livers of TO- treated wild type mice: Wild type C57Bl6 male 
mice were injected with 10ml/kg turpentine oil (TO), i.e. 100µl in each of the hind limb muscle to induce localised 
tissue injury. HO-1(A) and serum amyloid A-1 (B) mRNA expression analysis by quantitative RT-PCR in the liver 
of TO-treated mice (results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time 
point). (C) Northern blot analysis of the same mRNA shows the mRNA identification by size. (D) Western blot 
analysis of HO-1-protein in total liver homogenates (representative of one animal per time point). 
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Figure 4: 
Hepatic HO-1 and SAA-1 gene expression analysis in LPS-treated wild type mice: Wild type C57Bl6 male mice were 
intraperitoneally injected with 50µg of LPS from E.coli to produce systemic inflammation. Control animals received 
no treatment. HO-1(A) and serum amyloid A-1(B) mRNA expression analysis by quantitative RT-PCR in the livers 
of LPS treated mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time 
point). (C) Northern blot analysis shows the specific mRNA identity by size. (D) Protein expression analysis of HO-
1 in total liver homogenates by Western blot (representative of one animal per time point). 
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4.3 IL-6 upregulates hepatic HO-1 gene expression 
 
In order to confirm that IL-6 induces hepatic HO-1 mRNA, we treated mice intraperitoneally with 
recombinant IL-6 (Fig. 5). A statistically significant induction of HO-1 at 2h (1.44 ± 0.045 fold change, 
P<0.01) was observed. In IL-6 treated murine hepatocytes also, HO-1 was induced (Fig. 6). 100mg and 
1000ng were the doses of IL-6 that induced statistically significant induction of HO-1 in the mouse 
hepatocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: 
Effect of IL-6 on HO-1 gene expression: Mice were injected intraperitonealy 1000 units of interleukin 6 to analyze 
the time dependent kinetics of hepatic HO-1 (A)   HO-1 gene expression was analyzed by quantitative RT-PCR 
(Results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n= 2-3 animals per time point). (B) Northern 
blot analysis of HO-1 and SAA-1 (representative of one animal per time point). 
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Figure 6: 
HO-1 in IL-6 treated mice hepatocytes: Murine hepatocytes were treated with different doses of murine IL-6 and 
were harvested after 6h (A) Quantitative RT-PCR analysis of HO-1 mRNA induction in mouse hepatocytes (results 
represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=3 replicates per time point).  (B) Western blot 
analysis of HO-1 protein expression in mouse hepatocytes. 
 
 
 
 
4.4 Serum interleukin-6 closely correlates with hepatic HO-1 induction 
 
The concentration of IL-6 in the sera of TO- and LPS-treated wild type mice increased 
instantaneously (Fig. 7). In TO-treated animals, however, the statistically significant upregulation, as 
analyzed by t-test, was seen only at 4h (P=0.0276), 12h (P= 0.0094) and 24h (P=0.0269) after TO-
injection, whereas in LPS-treated wild type animals statistically significant increase of IL-6 amount was 
observed at 2h (P=0.0119), 4h (P=0.0098), 6h (P=0.0095) and 12h (P=0.0012) time points after injection. 
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Figure 7: 
Serum interleukin-6 concentration analyzed by ELISA (A) TO-treated C57Bl6 male mice. (B) LPS-treated C57Bl6 
male mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time point).  
 
 
4.5 HO-1 induction in IL-6 knockout mice 
 
HO-1 was upregulated at mRNA level after TO-treatment of IL-6 knockout mice (Fig. 8). 
However, unlike wild type mice, statistically significant induction of HO-1 in TO-treated IL-6 knockout 
mice was seen only at 2h (2.39 ± 0.29 fold change, P=0.0182). In LPS-treated IL-6 knockout mice also, 
HO-1 mRNA expression increased (Fig. 9) and significant changes were seen at 2h (P=0.0217), 4h 
(P=0.0191) and 24h (P=0.0127) post LPS injection.  
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Figure 8: 
HO-1 and SAA-1 mRNA expression in TO-treated IL-6 knockout mice liver: Male IL-6 knockout mice (B6.129S2-
IL6tm1Kopf/J) were injected 100µl turpentine oil in each of the hind limb muscle. Control animals received no 
treatment. HO-1(A) and SAA-1(B) mRNA expression analysis by quantitative RT-PCR in the livers of TO-treated 
IL-6 knockout mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time 
point). (C) Northern blot analysis to identify the specific transcripts by size. (D) Western blot analysis of HO-1 from 
total liver protein. 
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Figure 9: 
HO-1 and SAA-1 gene expression examination in LPS-treated IL-6 knockout mice liver: Male IL-6 knockout mice 
(B6.129S2-IL6tm1Kopf/J) were intraperitoneally injected with 50µg of LPS to induce systemic inflammatory 
response. Control animals received no treatment. HO-1(A) and SAA-1(B) mRNA expression analysis by quantitative 
RT-PCR in the liver of LPS-treated mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 
animals per time popint). (C Northern blot shows the specific mRNA, as identified by size. (D) Western blot analysis 
of HO-1 protein in total liver homogenates (representative of one animal per time point). 
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4.6 TNF-  and IL-1ß concentrations in serum of TO-treated wild type and IL-6 
knockout mice 
 
Overall, the serum levels of TNF- and IL-1ß are almost comparable in TO-treated wild type and 
IL-6 knockout mice (Fig. 10). In wild type animals the amount of IL-1ß increased significantly at 2h (P= 
0.0002), 6h (P= 0.0346), 12h (P= 0.0229) and 24h (P<0.0001), whereas no significant increase was seen 
for TNF- in the sera of these animals. In fact, a significant decrease of TNF- concentration was seen at 
24h (P= 0.0053). However, no significant changes were observed in serum TNF- levels in TO-treated 
IL-6 knockout mice, but significant increase of IL-1ß was evident at 2h (P= 0.0085)and 6h(P= 0.0239). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: 
Alterations of serum TNF- and IL-1ß concentrations of TO-treated mice: the two cytokines were measured in the 
serum of animals using ELISA kits from R&D (A) Serum TNF- and IL-1ß in TO treated wild type mice. (B) Serum 
TNF- and IL-1ß in TO treated IL-6 knockout mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by 
t-test; n=4 animals per time point). 
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In LPS treated wild type animals TNF- peaked at 6h in serum, although it was statistically non-
significant, a significant upregulation of serum TNF- was seen at 4h (P= 0.0088) in these animals, 
whereas in LPS-treated IL-6 knockout mice the peak in serum TNF- occurred at 2h (P= 0.0356) post 
LPS injection and it was statistically significant (Fig. 11). Changes in serum TNF- in these knockout 
mice were statistically significant also at 4h (P= 0.0073) and 12h (P= 0.0049) as well. In control animals 
IL-1ß was not detectable in the sera of both wild type and IL-6 knockout mice. But a significant 
upregulation in IL-1ß concentration was seen in the sera of both wild type (P= 0.0425) and IL-6 knockout 
mice (P = 0.0474) at 4h. However, in the sera of LPS treated wild type mice, IL-1ß declined to basal level 
at 12h whereas it was significantly high at 6h (P= 0.0047)and 12h (P= 0.0499) time points in knockout 
mice and returned to basal level at 24h(Fig. 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: 
TNF- and IL-1ß concentrations in the sera of LPS treated wild type and IL-6 knockout mice: (A) Serum TNF- 
and IL-1ß concentrations in LPS-treated wild type mice (B) Changes in the amount of TNF- and IL-1ß in the sera 
of LPS treated IL-6 knockout mice (results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=4 
animals per time point). 
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4.8 Determination of STAT-3 phosphorylation in the liver of TO- and LPS- 
treated mice 
 
IL-6 regulates HO-1 gene expression via STAT-3. In order to estimate the possible involvement 
of STAT-3 in the regulation of HO-1 gene expression in IL-6 knockout mice, STAT-3 phosphorylation 
was determined in the hepatic nuclear extracts of  TO- and LPS-treated IL-6 knockout mice using a 
specific antibody and was compared to their wild type counterparts (Fig. 12). It was interesting to note that 
STAT-3 followed more or less the same phosphorylation pattern in both wild type and IL-6 knockout mice 
in both types of acute phase response, however as seen in Western blot, the magnitude of phosphorylation 
appeared to be less in knockout mice when compared with their respective wild type animals using same 
amount of nuclear protein. 
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Figure 12: 
Hepatic STAT-3 phosphorylation analysis by Western blotting: STAT3 phosphorylation was analyzed by Western 
blot analysis with the hepatic nuclear extract of LPS- and TO-treated mice using a specific antibody that recognises 
only the phosphorylated form of STAT3. (A) STAT-3 phosphorylation analysis in the nuclear extract of LPS treated 
wild type mice. (B) Western blot analysis of phosphorylated form of STAT-3 in the nuclear extract of LPS-treated 
IL-6 knockout mouse liver. (C) STAT-3 phosphorylation was analyzed in the hepatic nuclear extract of TO treated 
wild type mice. (D) Western blot analysis of phosphorylated STAT-3 in the nuclear extract of TO-treated IL-6 
knockout mouse liver. 
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4.9 Distinct AP-1 and NF-κB DNA binding activity in liver of IL-6 knockout 
mice in two models of acute phase reaction 
 
AP-1 and NF-κB are the two distinctive transcription factors, well known to regulate 
inflammatory processes, and are also involved in the positive regulation of HO-1 gene expression 
regulation during APR. Their DNA binding activity was analyzed in the hepatic nuclear extracts of TO 
and LPS-treated IL-6 knockout mice (Fig 13& 14). In TO-treated animals AP-1 binding activity was high 
at 6h and 12h, whereas NFκB peaked at 24h. However, in LPS-treated animals NFκB peaked at 2h, 
whereas AP-1 binding to consensus DNA sequence started to increase at 2h, and it was maximum at 12h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: 
DNA binding activity of Activator Protein 1 (AP-1) and nuclear factor kappa-light-chain-enhancer of activated B 
cells( NF-κB) by gel mobility shift analysis: (A) AP-1 DNA binding activity was analyzed in the hepatic nuclear 
extracts of LPS treated IL-6 knockout mice using consensus oligos for AP-1 (B) DNA binding activity of NF-κB was 
analyzed in the hepatic nuclear extract of LPS treated IL-6 knockout mice using consensus oligos for NF-κB. 
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Figure 14: 
Activator Protein 1 (AP-1) and nuclear factor kappa-light-chain-enhancer of activated B cells( NF-κB) DNA binding 
activity by electro mobility shift analysis: (A) AP-1 DNA binding activity was analyzed in the hepatic nuclear extract 
of TO treated IL-6 knockout mice using consensus oligos for AP-1 (B) DNA binding activity of NF-κB was analyzed 
in the hepatic nuclear extract of TO treated IL-6 knockout mice using consensus oligos for NF-κB. 
 
4.10 Changes in cytokine gene expression in the liver and muscle of TO- and 
LPS-treated mice 
 
The serum levels of various acute phase cytokines changed in the two models of acute phase 
reaction. In order to determine the source of these cytokines and to analyze the effects of  TO- and LPS-
treatments on liver in our animal models, we analyzed the gene expression of IL-6, IL-1ß, IFN-γ gamma 
and TNF- in the liver of these animals by real time PCR. In TO-treated (Fig. 15) wild type mice, IL-6 
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expression increased in liver. TNF- mRNA expression levels did not increase significantly in both wild 
type and IL-6 knockout mice after TO-treatment. IFN-γ also remained almost unchanged. However, when 
we analyzed IL-1ß, an increase was seen in the liver of wild type mice, but no increase, rather a decrease, 
was seen in IL-6 knockout mice, but serum ELISA indicated an increase in IL-1ß levels in these animals. 
Therefore, in order to determine the source of serum IL-1ß we checked the cytokine-mRNA expression at 
the site of injury i.e., TO-injected hind limb muscle (Fig. 16). Significant increase in IL-1ß gene 
expression levels were seen by RT-PCR in the TO-injected hind limb muscles of both wild type and IL-6 
knockout mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: 
Pro-inflammatory cytokines mRNA expression analysis by quantitative real time PCR in the liver of TO-treated IL-6 
knockout mice (A), and their wild type equivalents (B): (results represent the mean value± s.e.m. (*P<0.05, analyzed 
by t-test; n=4 animals per time point). 
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In the LPS-treated animals a significant upregulation of all these pro-inflammatory cytokines was 
seen, and these changes in hepatic cytokines’ expression levels were very well in accordance with the 
serum levels of the cytokines in these animals (Fig. 17). However, in order to compare the TO-treated 
injured muscle with the skeletal muscle from LPS-treated animals, we analyzed the cytokines’ gene 
expression in the skeletal muscle of LPS-treated wild type and IL-6 knockout mice. It was interesting to 
note that the cytokines’ mRNA expression levels were significantly augmented in the non-injured hind 
limb muscle of LPS-treated animals. The magnitude of upregulation of TNF- and IFN-γ was comparable 
in wild type and IL-6 knockout mice. However, in case of IL-1ß a much higher and more prolonged 
upregulation of mRNA was seen in IL-6 treated mice (Fig. 18). 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: 
Gene expression analysis of various pro-inflammatory cytokines in the hind limb muscle by quantitative RT-PCR: 
TO-treated IL-6 knockout mice (A), and their wild type equivalents (B). (Results represent the mean value± s.e.m. 
(*P<0.05, analyzed by t-test; n=4 animals per time point). 
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Figure 17: 
Changes in hepatic gene expression of various pro-inflammatory cytokines in LPS treated IL-6 knockout mice by 
quantitative RT-PCR (A), and their wild type counterparts(B), analyzed by real time PCR (results represent the mean 
value± s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time point). 
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Figure 18: 
Various pro-inflammatory cytokines mRNA expression inspection by quantitative RT-PCR in the hind limb muscles 
of LPS treated IL-6 knockout mice (A), and their wild type counterparts(B) (results represent the mean value± s.e.m. 
*P<0.05, analyzed by t-test; n=4 animals per time point). 
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4.11 Hepatic HO-1 gene expression upregulation by IL-1ß, TNF- and IFN-γ 
 
In order to analyze the direct effects of different other cytokines on hepatic HO-1 gene expression, 
mice were intraperitoneally injected with these cytokines. The results from these experiments indicate that 
TNF- (Fig. 19), IL-1ß (Fig. 20), IFN-γ (Fig. 21) increased hepatic HO-1 gene expression. 
 
 
 
Figure 19: 
Time-dependent effect of TNF- on hepatic HO-1 mRNA expression: Mice were injected intraperitonealy with 2µg 
TNF- to evaluate the time-kinetics of hepatic HO-1 gene expression after TNF- injection. Livers were taken at 
different time points up to 48h. (A) Hepatic HO-1 mRNA expression analysis after TNF- injection in a time 
dependent manner by real time quantitative PCR (Results represent the mean value± s.e.m. *P<0.05, analyzed by t-
test; n=3 animals per time point). (B) Northern blot analysis of HO-1 and SAA-1. 
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Figure 20: 
Effect of IL-1 beta on hepatic HO-1 gene expression:  Mice were injected intraperitonealy with 2µg interleukin 1 
beta. Livers were excised at different time points after injection and quickly stored in liquid nitrogen. Quantitative 
real time PCR (results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=2 animals per time point) (A) 
and Northern blot (B) analysis of hepatic HO-1 and SAA-1 mRNA. 
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Figure 21: 
Regulation of hepatic HO-1 by IFN gamma: A group of mice was treated with IFNγ in a time dependent manner 
from 1h till 48h. Northern blot (B) and quantitative real time PCR (results represent the mean value± s.e.m. *P<0.05, 
analyzed by t-test; n=2-3 animals per time point) (A) analysis show the changes in hepatic HO-1 and SAA-1 mRNA 
expression in these animals.  
 
 
4.12 HO-1 gene expression analysis in the skeletal muscles of TO- and LPS-
treated wild type and IL-6 knockout mice 
 
HO-1 mRNA was upregulated in the injured muscle of TO-treated wild type and IL-6 knockout 
mice (Fig. 22); however, the statistical significance was seen only at 24h in wild type mice. Although non-
significant, but it appeared that the induction of HO-1 mRNA was delayed in the injured muscle of IL-6 
knockout mice, and the extent of upregulation of HO-1 mRNA was higher in wild type mice. In LPS 
treated animals (Fig. 23), HO-1 gene expression increased, but significant upregulation was seen only at 
12h in wild type mice and at 24h in IL-6 knockout mice. HO-1 gene expression was determined in the 
non-injured muscle of TO-treated wild type and knockout mice, and it was interesting to note that APR 
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resulted in an increase of HO-1 mRNA in the non-injured muscle of these TO-treated animals (Fig.23). 
This increase was statistically significant only in wild type mice. In TO-treated IL-6 knockout mice, the 
increase of HO-1 mRNA was not significant. 
 
 
 
 
 
 
 
 
 
Figure 22: 
HO-1 gene expression analysis by quantitative RT-PC, in the hind limb muscle of TO- and LPS-treated mice: (A) 
HO-1 mRNA in the injured hind limb muscle of TO-treated wild type mice. (B) HO-1 mRNA expression analysis in 
the injured muscle of hind limb of TO-treated IL-6 knockout mice (results represent the mean value± s.e.m. *P<0.05, 
analyzed by t-test; n=4 animals per time point). (C) HO-1 protein expression analysis in injured hind limb muscle of 
TO-treated wild type mice by Western blotting (D) Western blot analysis of HO-1 in the injured muscle of hind limb 
of TO-treated IL-6 knockout mice. 
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Figure 23: 
HO-1 gene expression analysis by quantitative RT-PCR in the non-injured muscle of LPS- and TO-treated mice: (A) 
HO-1 mRNA expression changes in the hind limb muscle of LPS treated wild type mice. (B) Changes in HO-1 gene 
expression in the hind limb muscle of LPS treated IL-6 knockout mice. (C) HO-1 mRNA expression in non-injured 
muscle of TO-treated wild type mice (D). HO-1 mRNA expression in non-injured muscle of TO-treated IL-6 
knockout mice (results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time point). 
 
4.13 Lactoferrin gene expression in liver 
Acute phase inflammation resulted in an increase of hepatic lactoferrin mRNA expression, and the 
magnitude and duration of this upregulation was found to depend on the causative stimuli of APR. In TO-
treated animals a significant increase in lactoferrin gene expression in liver was seen at 6h (P= 0.0139) and 
12h (P= 0.0220) and the level of mRNA was still rising at 24h (Fig 24). However, in LPS-treated wild 
type animals an immediate increase of lactoferrin mRNA at 2h (P<0.0001) was observed in the liver that 
peaked at 6h (P<0.0001) and then returned to basal level at 24h (Fig. 25).  The increase in lactoferrin 
mRNA was followed by an equivalent increase in protein synthesis. As for transferrin, it increased slightly 
but statistically significant at 4h (P=0.0235) in TO-treated animals and then its expression declined. In the 
livers of LPS-treated animals also its expression increased slightly but it was not significant, however in 
these animals a significant decrease of transferrin mRNA was seen at 6h (P=0.0122), 12h (P=0.0145) and 
24h (P=0.0463) (Fig. 24 &25). 
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Figure 24: 
Ltf and Tf gene expression regulation in the liver of TO- treated wild type mice: Wild type C57Bl6 male mice were 
injected with 10ml/kg turpentine oil (TO) i.e., 100µl in each of the hind limb muscle to induce localised tissue injury. 
(A) RNA expression analysis of lactoferrin and transferring by quantitative RT- PCR (results represent the mean 
value± s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time point) (B) Northern blot analysis to study transferrin 
mRNA expression (representative of one series of animals). (C) Western blot analysis of lactoferrin in total liver 
homogenate (representative of one animal per time point). 
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Figure 25: 
Hepatic lactoferrin and transferrin gene expression analysis in LPS-treated wild type mice: Wild type C57Bl6 male 
mice were intraperitoneally injected 50µg of LPS from E.coli to produce systemic inflammation. Control animals 
received no treatment. (A) Ltf and Tf mRNA expression analysis by quantitative RT-PCR in the liver of LPS-treated 
mice (Results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time point). (B) 
Northern blot analysis to study mRNA expression of Ltf and Tf (representative of one series of animals). (C)  Protein 
expression analysis of lactoferrin in total liver homogenate by Western blot (representative of one series of animals). 
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4.14 IL-6 induced lactoferrin gene expression in liver 
 
In order to determine the role of IL-6 to induce lactoferrin gene expression, mice were 
intraperitoneally injected with IL-6 (Fig. 26). IL-6 induced significant expression of lactoferrin mRNA 
and of the protein at 2h (P=0.0314) in the liver of these mice.  
 
Hepatocytes are the major cell population in liver and play a major role in the induction of acute 
phase response. In order to determine if the hepatocytes are able to produce lactoferrin under the influence 
of IL-6, murine hepatocytes were treated with different doses of IL-6 (Fig. 27). IL-6 significantly 
upregulated lactoferrin gene expression in the primary hepatocytes’ cell culture in a dose dependent 
manner (Fig. 27). Similar results were obtained by treating murine hepatic carcinoma cell line hepa 1-6 
with different doses of IL-6 (Fig. 28). Hepa 1-6 cells showed significant increase of lactoferrin mRNA 
with 0.1ng (P=0.0004), 100ng (P=0.0011), 500ng (P<0.0001) and 1000ng (P<0.0001) of IL-6. The 
changes in mRNA levels were followed by equivalent changes in protein expression in these cells (Fig. 
28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: 
 
Effect of IL-6 on Ltf gene expression: Mice were injected intraperitonealy with 1000 units of interleukin 6 to analyze 
the time dependent kinetics of hepatic Ltf expression (A)  Ltf gene expression was analyzed by quantitative RT-PCR 
(results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n= 2-3 animals per time point). (B) Northern 
blot analysis of Ltf and Tf (representative of one series). 
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Figure 27: 
IL-6 dependent regulation of Ltf mRNA: Murine hepatocytes were treated with varying doses of IL-6 and were 
harvested after 6 hours. Quantitative RT-PCR analysis of Ltf mRNA induction in mouse hepatocytes (results 
represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=3 replicates).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 28: 
IL-6 treated hepa 1-6 cells. (A) Ltf gene expression analysis by quantitative RT-PCR (results represent the mean 
value± s.e.m. (*P<0.05, analyzed by t-test; n=3 replicates). (B) Ltf gene expression analysis by Western blot. 
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4.15 Changes in lactoferrin gene expression in the liver of IL-6 knockout mice 
after TO- or LPS-injection 
 
IL-6 boosts lactoferrin gene expression and might be the major regulator of Ltf gene expression. 
However, under certain pathological conditions blocking IL-6 might prove helpful in controlling the 
inflammation, but lactoferrin itself is part of the protective mechanisms of the immune system and is able 
to reduce the severe impacts of oxidative stress at the molecular level. Therefore, blocking of IL-6 might 
also result in the inhibition of induction of Ltf during acute phase reaction and thereby rendering the 
individuals more vulnerable to deleterious impacts of inflammatory response. In order to determine if IL-6 
is the only inducer of lactoferrin in liver during APR and to further explore the specific role of IL-6 to 
regulate Ltf gene expression, we induced APR in IL-6 knockout mice with TO and LPS just like the wild 
type counterparts. Lactoferrin was induced in the liver of these animals even in the absence of IL-6, 
indicating that IL-6 is not the only inducer of hepatic lactoferrin during APR. In TO-treated IL-6 knockout 
mice magnitude of lactoferrin mRNA expression was comparable to that observed in their wild type 
counterparts. However an earlier decline of Ltf mRNA was seen in the knockout mice at 24h (P=0.0351) 
after the peak expression at 12h (P=0.0049) was revealed. mRNA expression changes were followed by 
equivalent adjustments of lactoferrin expression at protein level in the liver of TO-treated IL-6 knockout 
mice (Fig. 29). Transferrin showed a slight but significant decrease at 2h (P=0.0015), but otherwise its 
levels in liver remained almost the same during the time after TO-treatment. Furthermore, in LPS-treated 
IL-6 knockout mice (Fig. 30) the magnitude of upregulation of lactoferrin expression was much higher as 
compared to their wild type equivalents, and unlike LPS-treated wild type mice, in the knockout animals 
LPS resulted in an immediate increase in hepatic lactoferrin expression, although it was statistically non-
significant. However, as seen in the wild type mice, LPS injection resulted in a decline of transferrin 
mRNA expression in the liver of IL-6 knockout mice. The statistically significant changes were seen at 4h 
(P<0.0001), 6h (P=0.0024) and 12h (P=0.0005).  
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Figure 29: 
Ltf and Tf mRNA expression in TO-treated IL-6 knockout mouse liver: Male IL-6 knockout mice (B6.129S2-
IL6tm1Kopf/J) were injected with 100µl turpentine oil in each of the hind limb muscle. Control animals received no 
treatment. (A) Ltf and Tf mRNA expression analysis by quantitative RT-PCR in the livers of TO treated IL-6 
knockout mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time point). 
(B) Northern blot to analyze hepatic mRNA expression of Ltf and Tf (representative of one series of animals). (C) 
Western-blot analysis of Ltf from total liver protein. 
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Figure 30: 
Ltf and Tf gene expression examination in LPS-treated IL-6 knockout mouse liver: Male IL-6 knockout mice 
(B6.129S2-IL6tm1Kopf/J) were intraperitoneally injected with 50µg of LPS to induce systemic inflammatory 
response. Control animals received no treatment. (A) Ltf and Tf mRNA expression analysis by quantitative RT-PCR 
in the liver of LPS-treated IL-6 knockout mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; 
n=4 animals per time point). (B) Northern blot to study mRNA expression of Ltf and Tf in liver (representative of 
one series of animals). (C) Western blot analysis of Ltf in total liver homogenate (representative of one series of 
animals). 
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4.16 Serum lactoferrin levels 
Lactoferrin is a secretory protein. Therefore, lactoferrin levels in the sera of TO- and LPS-treated 
animals were determined using an ELISA kit. In TO-treated wild type animals there was an immediate 
increase in serum lactoferrin levels 2h and 4h (P=0.0397), which was followed by a statistically non-
significant drop in serum Ltf levels and then at 24h (P=0.0394) again a significant increase was seen in 
serum lactoferrin levels. However, in the sera of TO-treated IL-6 knockout mice, although slight increases 
were seen in serum lactoferrin levels in the initial hours of APR, but a statistically significant increase of 
serum lactoferrin was seen at 12h (P=0.0015) only, followed by a decline (Fig. 31).  On the other hand, 
LPS induced an immediate increase in serum Ltf levels in wild type mice starting at 2h (P=0.0344), 
peaked at 4h (P=0.0023), and then started declining at 6h (P=0.0023), 12h (P=0.0030) and 24h (P=0.0027) 
very constantly. LPS-treated IL-6 knockout mice also showed statistically significant upregulation of 
serum lactoferrin levels, immediately after the i.p. LPS injection (Fig. 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: 
Serum lactoferrin concentration analyzed by an ELISA (A) TO-treated C57Bl6 male mice. (B) TO-treated male IL-6 
knockout mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time point).  
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Figure 32: 
Serum lactoferrin concentration analyzed by ELISA: (A) LPS-treated C57Bl6 male mice. (B) LPS-treated male IL-6 
knockout mice (results represent the mean value± s.e.m. (*P<0.05, analyzed by t-test; n=4 animals per time point).  
 
 
 
 
 
4.17 Role of different cytokines in lactoferrin gene expression regulation 
 
After evaluating that although IL-6 enhances hepatic Ltf gene expression, but is not the only 
inflammatory signal that regulates Ltf gene expression during acute phase reaction, we analyzed how 
other acute phase cytokines affect lactoferrin gene expression in liver. 
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Intraperitoneal injection of TNF-α enhanced Ltf gene expression in liver (Fig. 33). Statistically 
significant increase of Ltf mRNA was seen 3h and 6h (P=0.0054) post TNF-α injection. In the same 
animals, after TNF-α injection, hepatic transferrin mRNA increased significantly at 0.5h, but then was 
continuously down regulated, although this decline was not statistically significant. Similarly, TNF-α 
treatment to hepa 1-6 cells resulted in a significant increase of Ltf mRNA at 3h (P=0.0083), 6h (P=0.0022) 
and 12h (P=0.0358) (Fig. 36A). 
IL-1ß treatment of mice could not increase lactoferrin mRNA statistically significant in mouse 
liver (Fig. 34), neither could the in vitro stimulation of IL-1ß to hepa 1-6 cells (Fig. 36B).  
Significant increase of hepatic Ltf mRNA was observed after 0.5h (P=0.0216), 1h (P=0.0337) and 
2h (P=0.0055) post intraperitoneal injection of IFN-γ (Fig. 35). Likewise, IFN-γ treatment to hepa 1-6 
cells resulted in a statistically prominent increase of Ltf mRNA at 3h (P= 0.0276), 6h (P= 0.0002) and 12h 
(P<0.0001) (Fig. 36C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: 
Time-dependent effect of TNF- on hepatic Ltf and Tf mRNA expression: mice were injected intraperitonealy with 
2µg TNF- to evaluate the time-kinetics of hepatic Ltf and Tf gene expression after TNF- injection. Livers were 
taken at different time points up to 48 hours. (A) Hepatic Ltf and Tf mRNA expression analysis after TNF- 
injection by quantitative real time PCR (Results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=3 
animals per time point). (B) Northern blot analysis of Ltf and Tf. 
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Figure 34: 
Effect of IL-1ß on hepatic Ltf gene expression:  Mice were injected intraperitonealy with 2µg interleukin 1ß. Livers 
were excised at different time points after injection and quickly stored in liquid nitrogen. (A) Quantitative real time 
PCR analysis of hepatic Ltf and Tf mRNA (results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=2 
animals per time point) and (B) Northern blot analysis of hepatic Ltf and Tf mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: 
Regulation of hepatic Ltf mRNA expression by IFN-γ: A group of mice was treated with IFN-γ in a time dependent 
manner from 1h till 48h. Northern blot (B) and quantitative real time PCR (Results represent the mean value± s.e.m. 
*P<0.05, analyzed by t-test; n=2-3 animals per time point) (A) analysis show the changes in hepatic Ltf and Tf 
mRNA expression in these animals.  
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Figure 36: 
Ltf gene expression analysis by quantitative RT-PCR in cytokines treated heap 1-6 cells: Cells were treated with 
100ng of each cytokine for different durations:  (A) Ltf expression in TNF- treated hepa 1-6 cells. (B) Ltf 
expression in IL-1ß treated hepa 1-6 cells (C) Ltf expression in IFN-γ treated hepa 1-6 cells (Results represent the 
mean value± s.e.m. *P<0.05, analyzed by t-test; n=3 repeats) 
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4.18 Lactoferrin expression in the injured and non-injured skeletal muscle after 
TO- and LPS-injection 
 
Ltf mRNA increased in the injured TO-injected skeletal muscle of WT and KO mice. However, at 
protein level a prominent difference in lactoferrin expression was observed in the TO-injected injured 
muscle of wild type and IL-6 knockout mice. In wild type animals, TO-injection resulted in a peak Ltf 
expression at protein level at 6h and then it declined to basal level till 24h. However, in the injured muscle 
of IL-6 knockout mice an early increase in Ltf expression at 2h was seen at protein level, and till 24h 
lactoferrin protein expression was still increasing in the injured muscle of these knockout mice (Fig. 37). 
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Figure 37: 
Ltf gene expression analysis in the hind limb muscle of TO- and LPS-treated mice: (A) Ltf mRNA in the injured hind 
limb muscle of TO-treated wild type mice by quantitative PCR. (B) Ltf mRNA analysis by quantitative PCR in the 
injured muscle of hind limb of TO-treated IL-6 knockout mice (results represent the mean value± s.e.m. *P<0.05, 
analyzed by t-test; n=4 animals per time point). (C) Ltf expression at protein level in injured hind limb muscle of 
TO-treated wild type mice.  (D) Western blot analysis of Ltf in the injured muscle of hind limb of TO-treated IL-6 
knockout mice. 
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In the non-injured muscles of TO and LPS-treated mice, Ltf mRNA expression was analyzed by RT-PCR. 
A statistically significant down regulation of Ltf mRNA was seen in the skeletal muscle of LPS-treated 
IL-6 KO mice, however no significant decrease was observed in their wild type counterparts. On the other 
hand, in the non-injured muscles of TO-treated IL-6 KO mice a significant upregulation was seen 12h post 
TO injection, but their wild type counterparts showed a down regulation of Ltf mRNA immediately after 
TO injection that was statistically significant (Fig. 38). 
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Figure 38: 
Ltf gene expression analysis by quantitative RT-PCR, in the non-injured muscle of LPS- and TO-treated mice: (A) 
Ltf mRNA expression changes in the hind limb muscle of LPS treated wild type mice. (B) Changes in Ltf gene 
expression in the hind limb muscle of LPS-treated IL-6 knockout mice. (C) Ltf mRNA expression in non-injured 
muscle of TO-treated wild type mice (D). Ltf mRNA expression in non-injured muscle of TO-treated IL-6 knockout 
mice (results represent the mean value± s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time point). 
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4.19 Serum and hepatic changes in iron concentration 
 
Figures 39 & 40 show changes in hepatic and serum iron concentrations in TO- and LPS-treated 
wild type and IL-6 knockout mice. Both treatments i.e. TO and LPS, resulted in a decrease of serum iron 
levels, and at the same time an increase of hepatic iron concentration in wild type and IL-6 knockout mice. 
Decrease in serum iron was inversely proportional to hepatic iron increase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: 
Iron measurement in liver and sera of wild type mice: (A) Hepatic and serum iron concentration in TO-treated wild 
type mice (B) Hepatic and serum iron concentration in LPS-treated wild type mice (results represent the mean value± 
s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time point). 
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Figure 40: 
Iron measurement in liver and sera of IL-6 knockout mice: (A) Hepatic and serum iron concentration in TO-treated 
IL-6 knockout mice (B) Hepatic and serum iron concentration in LPS-treated IL-6 knockout mice (Results represent 
the mean value± s.e.m. *P<0.05, analyzed by t-test; n=4 animals per time point) 
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5 Discussion 
 
The current study targeted HO-1 and Ltf gene expression regulation in two animal models of 
acute phase reaction. Liver and skeletal muscles were the organs of interest. The whole inflammatory 
process is primarily based on cytokines’ signalling cascades, which not only induce pro-inflammatory 
pathways but also provoke anti-inflammatory mechanisms to reduce the spread of inflammatory noxae. To 
treat inflammation related pathologies, it is best to understand the role of different individual 
inflammatory signalling molecules in mounting and resolving the whole acute inflammatory reaction. 
Keeping this in mind, cytokines’ dependent gene expression regulation of HO-1 and Ltf were studied in 
the current work.  Both, HO-1 and Ltf play an important role in iron metabolism and are important 
cytoprotective molecules, possibly having a great potential for being used as therapeutic targets for 
protection against inflammatory processes and oxidative tissue damage.  
5.1 Induction of inflammatory response 
Serum amyloid A (SAA) is the archetypal vertebrate acute phase protein. SAA-1 is the major 
isotype of all acute phase SAAs (Xu et al., 2006). All the four cytokines, i.e. IL-1ß, IL-6, TNF- and IFN-
γ induced SAA-1 gene expression very prominently in liver, indicating the induction of an APR in these 
animals. TNF- dependent induction of SAA has previously been reported in mouse liver (Ramadori et 
al., 1988) and human hepatocytes (Yap et al., 1991). Ramadori et al. (1988) have also shown the induction 
of SAA gene expression in mouse liver after IL-1ß and IL-6 treatment. 
Many cytokines are capable of exerting both positive and negative effects, depending on which 
cell they interact with and the context of interaction. Whereas the pro-inflammatory cytokines (e.g. TNF- 
, IL-1ß) mostly have up-regulating effects on aspects of inflammation and acute phase response, the anti-
inflammatory cytokines have in general down regulating effects (Jensen and Whitehead, 1998). 
Interleukin-6, a pleiotropic cytokine with a wide range of biological activities and produced by various 
cell types (Fig. 41) (Naka et al., 2002), has both pro- and anti-inflammatory properties. SAA is readily 
induced by IL-1ß or TNF-, and each of these cytokines can synergize with IL-6 to dramatically increase 
SAA production at mRNA and protein level (Ganapathi et al., 1988;1991). However, it is also known that 
IL-6 suppresses the production of IL-1ß and TNF- and thereby acting as an anti-inflammatory cytokine 
(Schindler et al., 1990;Xing et al., 1998). 
HO-1 and lactoferrin are part of the protective mechanism during oxidative stress, and IL-6 is 
involved in the induction of both. In the current investigation we studied the gene expression regulation of 
Ltf and HO-1 in TO- and LPS-treated IL-6 knockout mice. Some previous investigators have indicated the 
abrogated inflammatory response in IL-6 knockout mice during APR (Kopf et al., 1994;Gomez et al., 
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2006). To assess the induction and resolution of APR, we analyzed serum amyloid A-1 expression in the 
liver of TO- or LPS-treated IL-6 knockout mice and compared them to their wild type equivalents. In TO-
treated knockout animals mRNA of SAA-1 was increased lesser as compared to their wild type 
counterparts and it started declining earlier i.e. only after 12 h. As IL-6 is the principal mediator of TO 
induced APR (Knittel et al., 1997), the earlier resolution of inflammatory response in IL-6 knockout mice 
fits well in this model. On the contrary, in LPS treated animals, absence of IL-6 resulted in an increased 
hepatic SAA-1 gene expression, and therefore indicating an amplified inflammatory response in LPS-
treated knockout mice. LPS is known to be the major mediator of endotoxic shock (Immenschuh et al., 
1999), and pro-inflammatory cytokine TNF- alpha is the principal mediator of LPS-induced hepatic APR 
(Wijayanti et al., 2004). IL-6 exerts some restraining effects on TNF- expression (Ricchetti et al., 2004). 
This might explain the enhanced inflammatory response in this model of APR in IL-6 knockout mice, 
where TNF- probably exacerbates the inflammatory response due to lack of protective effect of IL-6.  
 
Figure 41: IL-6 producing cells and biological activities of IL-6: IL-6 is produced by lymphoid and 
nonlymphoid cells (top of figure) and has a wide range of biological activities on various target cells 
(bottom of figure) (Naka et al., 2002). 
Iron concentration is another index of assessing inflammation. In this work we also measured serum iron 
levels and iron concentration in the liver of the animals treated with TO or LPS, and we found an inverse 
correlation between the decrease of serum iron concentration and the increase of liver iron concentration.  
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5.2 Heme oxygenase-1 
 
5.2.1 HO-1 upregulation in two models of acute phase reaction in mice 
 
Liver is the main organ that reacts to any kind of acute phase stimuli (Sheikh et al., 2006). In the 
current study, hepatic HO-1 mRNA was upregulated in wild type mice after TO and LPS treatment. This 
upregulation of HO-1 transcript in our mice models was quite in accordance with previous APR studies in 
rat and mouse (Lee and Chau, 2002;Tron et al., 2005;Chang et al., 2006). But as different models of APR 
are characterised by divergent inflammatory mediators and altered pattern of acute phase proteins’ 
synthesis (Tron et al., 2005), the present comparison of the two APR models shows that the magnitude of 
increase of HO-1 mRNA and protein synthesis is different in the two mouse APR models. LPS resulted in 
an immediate increase at 2h, followed by a decline of hepatic HO-1 mRNA, whereas HO-1 gene 
expression in liver peaked at 4h after TO-treatment. The rise in mRNA was followed by an increased 
production of the protein. This rise in hepatic HO-1 protein was apparent only after 2h of LPS injection 
whereas in case of TO-treatment a clear increase of the peptide was evident after 4h. Although the mRNA 
of HO-1 declined to basal level in both mouse models of APR, the amplification of protein synthesis was 
still prominently visible even at 24h after the induction of APR in both the mice models. However, this 
can be explained by the fact that HO-1 mRNA has a half-life of about 3h, whereas the protein has a half-
life of about 15-21h (Srivastava et al., 1993). Hepatic HO-1 gene expression regulation has previously 
been studied by Lyoumi et al (1998) and Tron et al (2005) in a TO-induced acute inflammation model in 
rat. Lyoumi et al (1998) studied the hepatic HO-1 gene expression in LPS-induced APR in rat as well. But 
in both models of APR by Lyoumi et al. (1998), HO-1 gene expression was studied only at mRNA level 
using RT-PCR. Tron et al. (2005) studied protein expression in liver of TO-injected rats. In the current 
investigation we studied HO-1 gene expression in both animal models at mRNA as well as at protein 
level.  
At mRNA level, our results indicate that after TO or LPS injection hepatic HO-1 induction was 
slightly earlier in mouse than in rat at mRNA level. However, the results from Lyoumi et al (1998) 
support the current results in our mouse models in the pattern of induction of hepatic HO-1 mRNA. The 
magnitude of upregulation of hepatic HO-1 mRNA was higher after TO-injection as compared to LPS 
injection, and it was true for both, rat from Lyoumi and mouse from the current study. At protein level, 
however, our results differ from the results of Tron et al. (2005), who showed a start of increase of HO-1 
peptide at 2h which was still rising at 48h in rat liver. However, in our mouse model of TO-treatment HO-
1 peptide seemed to peak at 12h and then it started declining. In another study, Song et al. (2003) has 
shown an increase in hepatic HO-1 at protein level after treating mice with LPS, but their study differed 
from ours in the sense that we used a single dose of LPS and then studied its effects on hepatic HO-1 
expression at different time points till 24h. Song et al. (2003), on the other hand, used intravenous 
injection unlike our intraperitoneal treatment. Besides, to study time kinetics of HO-1 in liver after LPS 
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treatment, they injected 1, 2 or 3 doses of LPS every 24h. Therefore, the overall scenario in which they 
performed the experiments is different from our experimental protocols. However, both studies conclude 
that LPS augments HO-1 in liver. 
 
5.2.2 Role of IL-6 in the development of APR and in the induction of hepatic HO-1 
 
In some previous studies, Tron et al. have advocated the central role of IL-6 in gene expression 
regulation of HO-1 (Tron et al., 2005;Tron et al., 2006). In the current study, serum IL-6 levels were 
significantly amplified and were found to be closely correlated to HO-1 expression in the liver of wild 
type mouse. Besides, in IL-6 treated murine hepatocytes and hepa 1-6 cells, HO-1 expression also 
increased at mRNA and protein levels. These data are quite in accordance with the results obtained by 
Tron et al. in vivo and in vitro. The serum IL-6 levels were, however, still high even after the reduction of 
hepatic HO-1 mRNA. This phenomenon might be explained by the known fact that IL-6 induces down 
regulation of its cognate receptor, IL-6R, in vitro (Hoffmann et al., 1994). Moreover, it has been 
demonstrated that IL-6R mRNA expression in rat liver is markedly decreased 6-12h after TO 
administration (Geisterfer et al., 1993). Therefore, it is likely that continuously high levels of serum IL-6 
during APR subsequently lead to downregulation of the IL-6R, thus abolishing the action of IL-6 in the 
liver when it is not required anymore. 
 
In order to analyze the fundamental role of IL-6 in the regulation of HO-1 gene expression during 
APR, we utilized TO and LPS treatment in IL-6 deficient mice. In knockout mice, the constitutive 
expression of HO-1 was higher than in their wild type counterparts. The magnitude of HO-1 expression 
upregulation was comparable in two models of APR in knockout mice, but was lower than their wild type 
counterparts. However, at protein level TO treatment in the absence of IL-6 resulted in a delayed increase 
of HO-1 protein in liver, i.e. at 6h, but it peaked at 12h like in wild type mice and started to decline at 24h. 
Same delay was observed in LPS treated IL-6 knockout mice. Instead of 2h, as was seen in the LPS-
treated wild type mice, HO-1 peptide started to increase at 4h in knockout mice, but like their wild type 
counterparts reached at peak expression at 24h. These data indicate a mandatory role of IL-6 for an early 
translation of HO-1 in both models of APR. This kind of study in IL-6 knockout mice has not been 
reported by any other group so far. 
 
5.2.3 Role of other acute phase cytokines to induce HO-1 in liver during APR 
 
Using different kinds of experimental approaches, several groups have demonstrated that in 
addition to IL-6, HO-1 gene expression is also regulated by other pro-inflammatory cytokines like TNF-, 
IL-1ß and IFN-γ, as well (Song et al., 2003; Malaguarnera et al., 2005;Nairz et al., 2008).  In spite of the 
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similarities in general signs and symptoms, different in vivo models of the APR represent diverse patterns 
of acute phase mediators and plasma proteins release during the inflammatory process (Ramadori and 
Christ, 1999). For example, an LPS model is characterized by rapid circulatory increase of various pro-
inflammatory cytokines like IL-6, IL-1β, and TNF-α, all at the same time, causing systemic inflammation. 
The variety of mediators in this model makes it difficult to define the role of individual cytokines in the 
induction of certain proteins, particularly in liver. To determine the role of individual cytokines to induce 
HO-1 gene expression in the liver, we treated mice with different individual cytokines, like IL-6, IL-1ß, 
TNF- and IFN-γ. All these cytokines in our in vivo mouse models increased hepatic HO-1 mRNA. In 
order to assess the relative contribution of these cytokines to induce hepatic HO-1 mRNA in our models of 
APR in IL-6 knockout mice, we analyzed the gene expression of these cytokines in the liver and muscle 
and compared them to that of their wild type equivalents. All these cytokines were sufficiently upregulated 
in the liver of LPS-treated knockout mice, whereas in TO-treated animals the amplification of gene 
expression of these cytokines in the liver was not significant. However, serum ELISA indicated an 
increase in the levels of TNF- and IL-1ß in these animals that was comparable to their wild type 
counterparts. Therefore in order to locate the source, we quantified the mRNA expression of these 
cytokines at the site of injury, i.e. TO-injected-injured-muscle. All these cytokines were sufficiently 
upregulated in the injured muscle of IL-6 knockout mice and closely correlated to serum cytokine levels. 
Considering the time kinetics, IL-1ß levels in serum and in injured muscle correlated more to hepatic HO-
1 gene expression, as compared to TNF- in TO-treated IL-6 knockout mice and thus indicating the 
possibility of compensation of IL-6 by IL-1ß to regulate HO-1 gene expression in this animal model, 
whereas in LPS-treated knockout mice serum levels of both IL-1ß and TNF- started to increase 
concurrently at the start of APR and were closely associated to hepatic HO-1 mRNA expression level.  
 
5.2.4 Involvement of various transcription factors to regulate hepatic HO-1 gene expression 
 
Various cytokines induce HO-1 gene expression by activating different sets of transcription 
factors. IL-6 signalling is involved in the major regulation of a variety of acute phase proteins in 
hepatocytes and is predominantly mediated by the latent transcription factor signal transducer and 
activator of transcription 3 (STAT3) (Yoo et al., 2002;Grivennikov et al., 2009). STAT3 is essential not 
only for the induction of inflammatory response by the liver but is also involved in several anti-
inflammatory activities. Cytokines other than interleukin-6 that are able to promote STAT3 
phosphorylation include oncostatin M, leukaemia inhibitory factor,  leptin, IL-12, interferons, IL-10, 
GCSF and different growth factors (Maritano et al., 2004;Sakamori et al., 2007). STAT-3 phosphorylation 
is crucial for HO-1 gene expression regulation. STAT-3 inhibition results in  non-expression of HO-1 
mRNA (Ricchetti et al., 2004). Phosphorylation and activation of STAT3 in IL-6 knockout mice has been 
reported in a chronic liver injury model after CCL4 injection (Rio et al., 2008). The result of current work 
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demonstrate for the first time that hepatic STAT3 is activated during APR even in the absence of IL-6, and 
the pattern of activation/ phosphorylation is completely dependent on the nature of inflammatory stimuli. 
This observation led us to deduce that STAT3 might also be involved in the augmentation of hepatic HO-1 
mRNA expression in our animal models of IL-6 knockout mice. But STAT3 is not the only transcription 
factor involved in the regulation of HO-1 gene expression. Depending on the intensity and duration of 
stimuli, HO-1 activation involves various transcription factors, that themselves are regulated by various 
other inflammatory cytokines. Among these transcription factors, AP-1 and NFκB are the major 
transcription factors that can regulate HO-1 gene expression (Prawan et al., 2005). Both of these 
transcription factors are known to actively regulate various sets of genes under different stress conditions 
and are themselves regulated by various inflammatory cytokines directly or by various interacting 
inflammatory signalling cascades. Irrelevant to which cytokine plays a major role, we analyzed the DNA 
binding activity of AP-1 and NFκB that are well known to regulate HO-1 gene expression by these 
cytokines. 
 
In TO-treated IL-6 knockout mice, DNA binding activity of AP-1 started to intensify at 4h and 
peaked at 12h that is more relevant to HO-1 mRNA expression than NFκB, which showed a delayed DNA 
binding activity at 24h time point. But another picture was seen in LPS treated knockout animals, where 
the early upregulation of HO-1 at 2h closely correlated to increased NFκB DNA binding activity at this 
time point. Considering the time kinetics to give it a mechanistic rationale, AP-1 seemed to be a little 
irrelevant to regulate hepatic HO-1 mRNA expression in LPS-treated IL-6 knockout mice, although it is 
known to regulate the gene expression of HO-1 after LPS-treatment in wild type mice (Wijayanti et al., 
2004). 
 
5.2.5 HO-1 gene expression in skeletal muscle in two models of acute phase reaction 
 
HO-1 was upregulated at mRNA and protein level in the TO-treated injured muscle of both wild 
type and IL-6 knockout mice. These transcriptional changes support previously published data in rat 
injured muscle (Tron et al., 2005). Similarly, Vesely et al. (1998) showed HO-1 induction in skeletal 
muscle by hemin and sodium nitroprusside. Nonetheless, to our knowledge, at translational level no such 
study in injured muscle tissue of wild type and IL-6 knockout mice during APR has been reported so far.  
Elevated levels of HO-1 can significantly inhibit apoptosis in several cell types, and therefore its induction 
in muscle tissue represents a defensive response to ensure muscle cell survival during atrophy (Hunter et 
al., 2001). Comparison of HO-1 mRNA levels in the non-injured muscle of TO- and LPS-treated animals 
revealed that inspite of an increase of various pro-inflammatory cytokines in the non-injured muscle of 
LPS treated animals, there were no dramatic changes in HO-1 mRNA expression in the earlier time points 
but a significant increase of HO-1 mRNA was seen at 12h and 24h. Moreover the magnitude of increase 
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of HO-1 mRNA in the muscle of knockout mice was much less than in their respective wild type 
counterparts. HO-1 production in diaphragmatic-muscle after LPS treatment has previously been reported 
by Taille et al. (2001), and this group has also shown an increase of HO-1 protein expression at 24h in the 
diaphragm. However, no comparative study describing HO-1 expression regulation in the skeletal muscle 
under different kinds of stress conditions is available so far.   Contrary to LPS, an early increase of HO-1 
mRNA was seen in the non-injured muscle of TO-treated animals, although it was statistically not 
significant in IL-6 knockout mice. The increased expression of HO-1 represents an antioxidant response 
by the production of the antioxidant bilirubin and the removal of prooxidant heme (Kondo et al., 1992). 
 
5.3 Lactoferrin 
 
Lactoferrin holds a very basic position in immune response. Diverse physiological functions have 
been ascribed to lactoferrin, including regulation of cellular growth and differentiation, intestinal iron 
homeostasis, host defence during inflammations and protection against different types of cancer. Some of 
these functions clearly involve iron binding properties of lactoferrin, whereas in others lactoferrin appears 
to involve iron independent mechanisms (Ward and Conneely, 2004). The current work focused mainly on 
lactoferrin gene expression regulation under acute phase conditions rather than its physiological functions. 
 
5.3.1 Hepatic lactoferrin gene expression regulation during acute phase conditions 
 
Lactoferrin mRNA expression was upregulated in the liver of TO- and LPS-treated wild type 
animals. However, as both the animal models represent two different scenarios of acute phase 
inflammation, the pattern of regulation of hepatic Ltf gene expression was clearly dissimilar in the two 
models. In TO-treated animals an increase was seen at 4h and the level of mRNA was still rising at 24h. 
However, in LPS treated animals an immediate increase of lactoferrin mRNA at 2h was observed in the 
liver, and this increase returned to basal level at 24h. This is very typical for this animal model, i.e. an 
urgent increase of acute phase proteins followed by a quick return to normal levels, but in case of TO 
injection, where there is no direct liver injury and liver is only the target of locally released cytokines from 
the injured muscle, lactoferrin gene expression was still upregulated in liver. Lactoferrin is a key element 
in the mediation of immune response and is known for its coordinated interaction between innate and 
adaptive immune response. Moreover, lactoferrin is involved in the reduction of inflammatory response 
and is able to reduce the severe impacts of oxidative stress at molecular level (Actor et al., 2009). To our 
knowledge, lactoferrin gene expression in various animal models of acute phase response has not been 
reported so far.  
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TO- and LPS-treatment result in oxidative stress and induction of lactoferrin after these treatments 
can be a key step towards the resolution of this inflammatory stress. The results of the current study lead 
us to deduce that lactoferrin gene expression is highly dependent on the nature of insult that the defence 
system of the body faces. In case of TO-induced localised tissue injury, the magnitude of upregulation of 
hepatic lactoferrin expression was lesser than that of LPS-induced hepatic injury. The increase in mRNA 
levels of hepatic lactoferrin was followed by equivalent changes in hepatic lactoferrin gene expression at 
protein levels. And at protein level also it was very clearly observed that LPS-treatment is a more potent 
inducer of lactoferrin peptide as compared to TO-treatment. 
 
For comparison we used transferrin gene expression in liver. Transferrin is the major known iron 
transporter in the body. Tf carries iron from the intestine, reticuloendothelial system and liver 
parenchymal cells to all proliferating cells in the body. Diferric Tf interacts with the TfR1 and is 
internalized by receptor-mediated endocytosis (Frazer and Anderson, 2005). It was very evidently seen 
that when lactoferrin gene expression increased, transferrin expression decreased in the liver of LPS-
treated animals. Same applies in TO-treated animals. TO-injection resulted in a slight upregulation 
followed by a down regulation of Tf gene expression. Sheikh et al. (2007) have also reported a similar 
pattern of Tf in the liver of rat after TO-treatment. In our experiments, at the same time points when Tf 
was decreasing lactoferrin expression increased. Furthermore, when these changes in transferrin and 
lactoferrin gene expression were occurring, serum iron was decreasing, but with an increase in hepatic 
iron pool. Therefore lactoferrin fits well in the situation, because under oxidative stress, when reactive 
oxygen species (ROS) are generated, they probably result in the drop of pH, and at low pH, transferrin is 
unable to bind iron effectively and therefore lactoferrin is increased in order to assist chelation of iron and 
to avoid spread of oxidative stress generated by free iron. Cairo et al. (1994) showed an early upregulation 
of transferrin with a subsequent down regulation in the liver when the iron was depleted from the 
circulation .  
 
Lactoferrin is a secretory protein (Brock, 1995). However, no previous study has reported its 
secretion from hepatic cells. In order to determine that hepatic cells secrete it or not, we did Ltf 
immunoprecipitation from two hepatic carcinoma cell lines. These results proved that hepatic cells are 
also able to secrete lactoferrin into serum, and when in serum, lactoferrin can be easily transported to other 
inflammatory cells in different organs, thus giving it a broader range of action. There, this lactoferrin 
interacts with the mononuclear cells and suppresses the production of different pro-inflammatory 
cytokines like TNF-α, IL1-ß and IL-6, and therefore tends to smooth the effects of the inflammatory 
cytokines at the site of infection or injury (Crouch et al., 1992). Suppression of inflammation by 
lactoferrin has also been reported in other studies. Peen et al. (1998) reported that intravenously 
administered lactoferrin to rat specifically accumulated in the kupffer cells. Yamaguchi et al. (2001) also 
signified the role of Kupffer cells as the site of action for lactoferrin in LPS-treated mice. Their study 
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indicated that if the Kupffer cells were suppressed by gadolinium chloride the levels of TNF-α were 
significantly reduced and so were the serum ALT levels thus indicating lesser liver injury. They got the 
same results with LPS treatment when the mice were intravenously treated with lactoferrin before. Besides 
this, in their in vitro and ex vivo experiments they clearly demonstrated that lactoferrin administered 
before LPS treatment significantly diminished TNF-α expression by Kuppfer cells due to its direct 
interaction with these cells. These results are also supported by another study where carrageenan induced 
TNF-α and IL-6 production was suppressed by cultured spleenocytes when the animals were orally treated 
with lactoferrin (Zimecki et al., 1998). Choe and Lee(1999) have also shown the same type of results with 
the mouse monocyte cell line Raw 264.7 and with human monocytic cells, i.e. THP-1 cells. They also 
studied the capability of lactoferrin to induce TNF-α in these cells, and their results indicate that 
lactoferrin itself does not have a good potential as an inducer of TNF-α and NO. They also analyzed if 
lactoferrin could induce NO production in aortic vascular smooth muscle cells, but the results were 
negative. Therefore, the control of lactoferrin gene expression during oxidative stress can prove to be a 
promising strategy in clinical practices. 
 
The serum lactoferrin increased significantly after TO- and LPS-injections, however, as seen with 
hepatic Ltf mRNA and protein expression, the pattern of increase of serum Ltf was different in the two 
models. In TO-treated wild type animals there was an immediate increase in serum lactoferrin levels. This 
immediate increase after TO-injection might be due to the invading neutrophils into the TO-injected 
muscle. After a sudden increase, there was a drop in serum Ltf levels and then at 24h again an increase 
was seen. This second increase in Ltf concentration in serum might represent the lactoferrin released from 
the liver that also peaked at 24h. On the other hand, although LPS also induced an immediate increase in 
serum Ltf levels at 2h, but this increase was more pronounced than that after TO-treatment to wild type 
animals, and in these animals lactoferrin steadily kept on rising till 4h and then started to decline 
afterwards very constantly. The increase in serum lactoferrin closely correlated to hepatic lactoferrin 
expression in these animals. Only a single peak of serum lactoferrin was seen in LPS-treated animals. This 
lead us deduce that liver is the major source of serum lactoferrin in the LPS treated animals, and 
neutrophils which are the major cell population that invade liver after the LPS-induced direct injury, might 
be the main source of this serum lactoferrin in these animals. 
 
5.3.2 Lactoferrin gene expression regulation by interleukin-6 
 
IL-6 is the principal mediator of acute phase response (Stenvinkel et al., 2002) as well as a key 
player in the regulation of iron metabolism (Marques et al., 2009). In order to determine the role of IL-6 to 
induce lactoferrin gene expression, we injected mice intraperitoneally with IL-6. IL-6 induced significant 
expression of lactoferrin in the liver of these mice. Hepatocytes are the major cell population in liver and 
play a major role in the conduction of APR (Sheikh et al., 2006). In order to determine whether 
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hepatocytes are able to produce lactoferrin under the influence of IL-6, we treated murine hepatocytes 
with different doses of IL-6. IL-6 significantly induced lactoferrin in the primary cell culture of murine 
hepatocytes. Furthermore, we treated murine hepatic carcinoma cell line hepa 1-6 with different doses of 
IL-6, and the data from this experiment also confirmed the previous results of lactoferrin induction by IL-
6 in murine liver and hepatocytes. The changes in mRNA levels were followed by an equivalent increase 
in protein expression in hepa 1-6 cell line.  
 
To understand the role of IL-6 in regulating iron metabolism by Ltf during acute phase response 
has remained one of our main focuses in the course of this investigation. Therefore, to further explore the 
specific role of IL-6 to regulate Ltf gene expression, we treated IL-6 knockout mice with TO and LPS just 
like the wild type mice. In TO-treated IL-6 knockout mice lactoferrin expression started to increase at 6h 
and was comparable to their wild type counterparts, peaked at 12h, but unlike the wild type mice, Ltf 
mRNA started to decline at 24h which was also followed by lactoferrin expression at protein level in the 
livers of these TO-treated IL-6 knockout mice. The early decrease in hepatic lactoferrin expression can be 
a direct effect of absence of IL-6, or may be due to decreased inflammation and early resolution of 
inflammatory process, as shown by Saa-1 expression in TO-treated-IL-6 knockout mice. Transferrin 
showed a slight decrease at 2h, but otherwise its levels in liver remained almost the same during the whole 
treatment time in these knockout animals after TO-treatment. On the other hand, in LPS-treated IL-6 
knockout mice, a different picture was seen. The magnitude of upregulation of lactoferrin expression after 
LPS treatment was much higher in the liver of knockout mice as compared to their wild type equivalents. 
Secondly, unlike LPS-treated wild type mice, in the knockout animals LPS resulted in an immediate peak 
in hepatic lactoferrin expression. This might be due to the fact that IL-6 suppresses the impact of TNF- 
(Xing et al., 1998), which is another major regulator of hepatic APR after LPS treatment. And therefore, in 
the absence of IL-6, TNF- resulted in a higher gene expression of lactoferrin. But if this is the case, then 
this also indicates that TNF- might be the more potent inducer of Ltf. The same early increase in 
lactoferrin expression in LPS treated IL-6 knock mice liver could also be seen at protein level as well. 
 
At serum level also, IL-6 knockout mice behaved differently than their wild type equivalents. In 
the sera of TO-treated IL-6 knockout animals, only one peak of lactoferrin was seen at 12h unlike the 
biphasic increase in their wild type counterparts. And in LPS-treated animals serum lactoferrin levels 
increased like in wild type mice, but the decrease in serum concentration of lactoferrin was delayed in 
these animals. The overall picture, therefore, leads us to deduce that under different acute inflammatory 
conditions IL-6 plays an important role to regulate lactoferrin gene expression. However, it is still to be 
determined whether this change in lactoferrin gene expression is due to the direct effect of IL-6 absence in 
the knockout mice or is an indirect consequence of altered pattern of inflammation in general in these 
animals. 
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5.3.3 Lactoferrin gene expression regulation by TNF- 
 
TNF- was found to upregulate hepatic Ltf gene expression in the in vivo experiments. In order to 
support the in vivo data, in vitro experiments were performed. TNF- increased lactoferrin gene 
expression in the in vitro experiments as well. TNF- serum levels did not increase significantly in TO-
treated wild type and IL-6 knockout mice, indicating that it is not the major player in localised-tissue-
injury-induced acute phase response.  However, in case of LPS-treatment TNF- is the major signalling 
molecule. TNF- increased the expression of lactoferrin gene in the in vivo and in vitro experiments. 
Therefore there is a great possibility that in case of LPS treatment, TNF- might be the major inducer of 
lactoferrin gene. And as indicated previously, IL-6 inhibits TNF- expression. So in IL-6 knockout mice 
the magnitude of increase of TNF- was higher after LPS-treatment, and so was lactoferrin expression. 
Furthermore, in LPS treated wild type and IL-6 knockout mice the time kinetics of serum TNF- 
concentration were closely correlating to hepatic Ltf expression. 
5.3.4 IL-1ß dependent lactoferrin gene expression regulation 
 
IL-1ß is another important regulator of acute phase response (Plackett et al., 2007) and of iron 
metabolism (Inamura et al., 2005). Serum levels of IL-1ß rose after both TO- and LPS-treatment. In order 
to analyze the impact of IL-1ß on hepatic lactoferrin gene expression, we injected mice intraperitoneally 
with recombinant IL-1ß and also treated mouse hepa 1-6 cells with recombinant murine IL-1ß. Our in 
vitro and in vivo result indicated that IL-1ß might not be among the signalling molecules that are 
regulating lactoferrin gene expression, as we saw no significant changes in lactoferrin gene expression in 
the liver of IL-1ß-treated mice or in IL-1ß-treated hepa 1-6 cells.  
5.3.5 Hepatic lactoferrin gene expression regulation by IFN-γ 
 
Gamma interferon (IFN-γ) is an important cytokine in the host defence and induces a variety of 
physiologically significant responses that contribute to immunity (Shtrichman and Samuel, 2001). IFN-γ 
mRNA expression did not change significantly in the liver of TO- and LPS-treated wild type mice. It also 
remained unchanged in TO-treated IL-6 knockout mice, but IFN-γ gene expression increased significantly 
in the liver of LPS-treated IL-6 knockout mice. Treatment of animals and hepa 1-6 cells with IFN-γ 
resulted in an upregulation of lactoferrin RNA. This might explain the continuous increased levels of 
serum lactoferrin in LPS-treated IL-6 knockout mice. In LPS-treated animals multiple signalling pathways 
are activated at the same time. Although TNF- is an important inducer of acute phase proteins after LPS-
treatment, but considering the time kinetics of serum TNF-, there were no big differences in LPS-treated 
wild type and IL-6 knockout mice. However, in LPS-treated IL-6 knockout animals continuously elevated 
levels of serum lactoferrin could be due to changed IFN-γ expression in these animals. Because of limited 
amount of mouse serum, it was not possible to measure serum IFN-γ levels in the current study, but the 
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possibilities of involvement of some other unknown pathways to regulate Ltf gene expression in these 
animals still remain. 
 
5.3.6 Lactoferrin gene expression regulation in the injured skeletal muscle of TO-treated animals 
 
In TO-injected skeletal muscle, lactoferrin expression was markedly different in wild type and IL-
6 knockout mice. In wild type mice Ltf expression peaked at 6h and then declined, however, in knockout 
mice’ injured muscles it kept on increasing till 24h. In injured muscle inflammatory cells like neutrophils 
may be the main source of lactoferrin after TO-injection. The elevated levels of Ltf  in the injured muscle 
of TO-treated IL-6 knockout mice indicate that probably due to lack of anti-inflammatory effects of IL-6 
in the late time points of acute inflammation, inflammatory cells keep on entering the injured muscle. The 
role of lactoferrin in this scenario can be both as anti-bacterial agent and as an iron chelator. 
 
5.4 Concluding Discussion 
 
Under inflammatory conditions innate immune system activates both pro- and anti-inflammatory 
signalling pathways. Therefore on one hand it tends to get rid of the inflammatory stimuli, but on the other 
hand at the same time, it tries to protect the body from excessive damage induced by pathogenic factors or 
by pro-inflammatory agents. To control the immune system from lending excessive damage to the 
organism, inflammatory signals’ manipulation can prove to be a secure approach for the treatment of a 
number of diseases. Among these signals, IL-6 holds a key position. It is considered as the emergency 
cytokine of the innate immune system to initiate the development of APR. The anti-inflammatory role of 
this cytokine has not been discussed in detail so far, neither the effects of this cytokine on the gene 
regulation of acute phase proteins that are involved in the resolution of acute phase inflammation. Under 
certain pathological conditions, blocking IL-6 might prove helpful in controlling the inflammation by 
avoiding the activation of genes that aggravate the inflammatory conditions, but on the other hand it must 
be taken into consideration that this blockade should not affect adversely the healing mechanisms of the 
organism. The results of the current work suggest that absence of IL-6 during tissue trauma or certain 
bacterial infection does not result in the obstruction of HO-1 and Ltf, the two genes that are not only 
regulated by IL-6, but can prove to be the major therapeutic targets to control inflammation. Furthermore, 
STAT-3, that is a main transcription factor in IL-6 related signalling, was still active, indicating the proper 
activation of different downstream signal. Among different other inflammatory cytokines that induced 
HO-1 expression individually also, i.e. TNF-, IL-1ß and IFN-γ were sufficiently upregulated in serum to 
create an APR, although as shown by SAA-1, these were not sufficient to maintain the inflammation after 
localised tissue injury in the absence of IL-6, but an exaggerated inflammatory response was seen in the 
LPS-treated knockout animals due to the lack of protective anti-inflammatory effects of IL-6. The overall 
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picture indicates that blocking IL-6 in both the inflammatory conditions, i.e. sepsis and tissue trauma 
might prove to be useful to control inflammation to a certain extent, but it might prove to be more 
promising in case of tissue trauma. However, in both cases, blocking IL-6 does not abolish the protection 
by HO-1 
 
As for lactoferrin, it proved to behave like a positive acute phase protein that is probably tending 
to compensate for the lack of activity of transferrin to chelate iron under acidic conditions of oxidative 
stress. Lactoferrin gene expression upregulation was also dependent on the nature of inflammatory stimuli. 
Therefore its expression was more pronounced after LPS-treatment than TO-injection mediated acute 
phase response. Both animal models have their distinct pattern of regulation of acute phase mediators. 
Among these mediators, when studied individually, TNF-, IL-6 and IFN-γ appeared to be involved in the 
induction of Ltf whereas IL-1ß seemed to be irrelevant to affect this arm of the innate immunity. 
 
The eventual objective of research aimed at understanding inflammatory process is to come up 
with strategies to control inflammation in situations that are harmful to patients or to stimulate the immune 
system where it is compromised. Targeting of HO-1 and lactoferrin for therapeutic benefits is getting 
widely acknowledged. Therefore, a better understanding of HO-1 and Ltf gene expression regulation 
during APR will lead towards the development of improved and more sophisticated therapies. 
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6 Summary 
 
Iron is indispensable to living organisms. Iron homeostasis is orchestrated both at the cellular and 
the systemic level, and liver plays a central role in the regulation of iron metabolism. An increasing 
number of genes associated with hepatic iron transport or regulation have been identified. Heme 
oxygenase-1(HO-1) and lactoferrin (Ltf) are among these genes known to regulate iron metabolism at 
cellular and systemic levels, respectively.  Heme-oxygenase-1 is an intracellular positive acute phase 
protein and regulates one of the pathways that hepatic cells utilize to acquire free iron. The cytokines 
regulating HO-1 gene expression in liver and in other organs like muscle are only partially known. 
Moreover, lactoferrin serum concentration is known to increase under acute phase conditions, but the site 
of synthesis in not known.  
 
In the current work we investigated the changes in HO-1 and Ltf gene expression during 
turpentine oil- and LPS-induced acute phase reaction (APR).  Cytokines are the core mediators of APR, 
and among different acute phase mediators IL-6 is one of the principle signalling molecules. It is known to 
play a key role in maintaining body iron homeostasis during APR. For this reason we studied the induction 
of HO-1 and Ltf in IL-6 treated mice, and in addition we generated TO- and LPS-induced APR in IL-6 
knockout (KO) mice to determine the effects of IL-6 absence on HO-1 and Ltf-gene expression regulation 
during APR. In order to evaluate the relative contribution of other acute phase cytokines to regulate HO-1 
and Ltf-gene expression, we treated mice with IL-1ß, TNF-, and IFN-γ. The in vivo results were 
supported by in vitro experiments, using the same cytokines in cell culture.  
 
IL-6 augmented the gene expression of HO-1 in IL-6 treated mice, murine hepatocytes and hepa 
1-6 cells. Serum IL-6 levels of TO- and LPS-treated wild type mice were elevated and closely correlated 
to the upregulation of hepatic HO-1 expression in these animals. Hepatic HO-1 gene expression was found 
to be increased significantly in IL-6 KO mice as well, in both the models of APR. In IL-6 KO mice, 
however, the constitutive expression of HO-1 in the liver was higher than in their wild type (WT) 
counterparts. Among other inflammatory signals, TNF-, IL-1ß and IFN-γ increased HO-1 gene 
expression in vivo and in vitro. Serum IL-1ß showed a delayed increase in TO-treated IL-6 KO mice as 
compared to their WT counter parts, but serum levels of TNF- did not augment significantly in these 
animals. In LPS-treated WT and IL-6 KO mice, the serum levels of TNF- and IL-1ß elevated 
prominently. We studied also the different transcriptional regulators of HO-1 in the liver of TO- and LPS-
treated IL-6 knockout mice. Among these, hepatic STAT3-phosphorylation was observed in both acute 
phase models in knockout mice. Among other transcriptional regulators of HO-1, AP-1 appeared to be 
more involved in TO-treated animals whereas NFκB was prominent in LPS treatment. HO-1 was induced 
also in injured and non-injured muscles of TO- and LPS-treated WT and IL-6 KO mice. However, 
whereas in TO-treated animals an early increase of HO-1 gene expression was measurable in non-injured 
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muscle, HO-1 was induced only at later time points in the muscle of intraperitoneally (i.p.) LPS-treated 
animals.  
 
Lactoferrin was upregulated at mRNA and protein level in the liver of TO- and LPS-treated WT 
mice, although the pattern of induction was different in both animal models. IL-6 induced lactoferrin gene 
expression in WT mice, murine hepatocytes and hepa 1-6 cells.  Lactoferrin gene expression also 
increased in the liver of TO- and LPS-treated IL-6 KO mice. The magnitude of upregulation was similar in 
WT and IL-6 KO mice, but an early decline in Ltf at mRNA and protein level was observed in TO-treated 
IL-6 KO animals. On the other hand, magnitude of upregulation of Ltf mRNA in the liver of LPS-treated 
IL-6 KO mice was higher than in the WT mice. Moreover, in TO-injected skeletal muscle also marked 
differences were seen in Ltf expression between WT and IL-6 KO mice. As compared to WT mice, IL-6 
KO mice showed a higher increase and a delayed decline in Ltf expression in the skeletal muscle after TO-
injection. Serum measurement of Ltf showed an increase of Ltf that was more prominent after LPS 
injection than after TO-injection. Besides IL-6, TNF- and IFN-γ also increased Ltf gene expression in 
vivo and in vitro. However, IL-1ß appeared to play no significant role in Ltf gene expression upregulation. 
 
HO-1 remains a positive acute phase protein, not only in liver but also in skeletal muscle under 
different acute phase conditions even in the absence of IL-6. Besides, the data acquired from the current 
work not only shows for the first time muscle and liver as two main sources of serum lactoferrin during 
different acute phase conditions, but also brings to light different acute phase signals regulating Ltf gene 
expression during acute phase conditions. In addition to Ltf and HO-1, serum iron levels and iron 
concentration in the liver-tissues of TO- and LPS-treated animals were measured, and an inverse 
correlation between the decrease of serum iron concentration and the increase of liver iron concentration 
was found in both the animal models. Increase in liver iron concentration closely correlated to augmented 
hepatic HO-1 gene expression, which is one of the pathways that hepatic cells utilize to acquire free iron 
by the breakdown of heme. At the same time, increase in hepatic Ltf gene expression indicates to a cyto-
protective pathway that might not only be involved in the chelation of free iron during APR, but also 
might be assisting in iron transport from serum to liver to reduce the possibility of free iron being 
available to pathogens in an ongoing APR. Whereas Ltf serum level increase during APR might probably 
be another protective mechanism of the immune defense system to chelate any free iron on one side or to 
transport iron into the area of need. 
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